



Shyamasundaran Kottlil, MD, PhD
Professor, Department of Medicine
Institute of Human Virology
University of Maryland School of Medicine

Date June 30, 2017

Contact Information

Business Address: 725 W Lombard Street
Room S222
Baltimore, MD 21201

Business Phone: 410-706-8927

Fax : 410-706-2499

E-mail:

skottlil@ihv.umaryland.edu

skottlil@niaid.nih.gov

Foreign languages: Malayalam (Proficient); Hindi (Fluent); Tamil (Fluent); Sanskrit (Fluent)

Education

1991 MD, Medical College, Trichur, Kerala, India

1993-1997 Ph.D. in Immunology (Faculty of Medicine) from Memorial University of Newfoundland, St. John's, NF

Postgraduate Education and Training

1991-1993 Postgraduate Training, Medical College, Calicut, Kerala, India

1997-2000 Internal Medicine Residency Program at Brown University School of Medicine, USA

1997-2000 Resident, Free HIV Clinic at Notre Dame Ambulatory Clinic, Central Falls, RI

2000-2003 Infectious Diseases Fellowship with Dr. Anthony S. Fauci at National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

Certifications:

2000-2010 ABIM Board Certified in Internal Medicine

2002-2012 ABIM Board Certified in Infectious Diseases

2010-2020 ABIM Board re-certified in Internal Medicine

2012-2022 ABIM Board recertified in Infectious Diseases

Medical Licensures

2001-present Commonwealth of Virginia Board of Medicine, Active
2009-present District of Columbia, Department of Health Board of Medicine, Active
2014-present State of Maryland Department of Health and Mental Hygiene/
Maryland Board of Physicians, Active

Employment History

Academic Appointments

2003-present *Faculty*, Washington D.C. Community Outreach PACT Program
2005-present *Faculty*, NIH International Society of Infectious Diseases HIV Training Program
2010-present *Visiting Professor*, Institute of Liver and Biliary Sciences, New Delhi, India
2010-present *Faculty*, Liver Immunology Laboratory, Institute of Liver and Biliary Sciences, New Delhi, India
2014- present *Professor*, Medicine, University of Maryland School of Medicine, Institute of Human Virology, Baltimore, MD

Other Employment

April 2003- present *Staff Clinician*, Immunopathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
July 2009-present *Scientific Director*, NIH-District of Columbia Program for AIDS Progress

Professional Society Memberships

1996-present *Member*, International AIDS Society (IAS)
1997-present *Member*, American College of Physicians (ACP)
1999-present *Member*, American Society of Microbiology (ASM)
2000-present *Member*, Greater Washington Infectious Diseases Society (GWIDS)
2008-present *Member*, American Association for the Study of Liver (AASLD)
2009-present *Member*, International Society for Interferon and Cytokine Research (ISICR)
2012-present *Member*, Infectious Diseases Society of America (IDSA)
2012-present *Member*, European Association of the study of Liver (EASL)
2015-present *Member*, Asia-Pacific Association of the Study of the Liver (APASL)

Honors and Awards

1993 Awarded Memorial University of Newfoundland Fellowship to pursue graduate studies

1994	Obtained the Memorial University of Newfoundland Immunology Graduate Program prize.
1995	Obtained ECFMG certificate.
1996-1997	Co. Investigator National Human Resources Development Program (NHRDP)
1997	Canadian Society of Immunology Scholarship
1998	Obtained USMLE Step 3 licensing exam in December 1998.
2005	Clinical Curriculum Certificate with Commendation
2005	NIH Bench to Bedside award recipient
2006	NIH Bench to Bedside award recipient
2007	NIH Bench to Bedside award recipient
2007	NIAID DIR Supplemental award recipient
2009	NIAID DIR Supplemental award recipient
2009	Office of AIDS Research (OAR) cycle 2 award recipient
2009	Office of AIDS Research (OAR) cycle 3 award recipient
2010	Office of AIDS Research (OAR) cycle 1 award recipient
2010	Distinguished Mentor award nominee
2010	NIAID DIR Supplemental award recipient
2011	NIH Bench to Bedside award recipient
2011	Office of AIDS Research Award (OAR) cycle1 award recipient
2012	NIH Bench to Bedside award recipient
2012	Fellow, American College of Physicians
2014	NIAID Outstanding Mentor Award recipient
2014	NIAID Merit AWARD for Innovations in Science
2015	Clinical Publication of the Year Award (Univ of MD School of Medicine)
2015	Fellow of the Infectious Diseases Society of America (FIDSA)
2016	Clinical research Forum Top Ten Manuscript (Osinusi et al JAMA 2015)
2016	Fellow at The American Society of Clinical Investigation (ASCI)
2017	Full tenure at the University of Maryland School of Medicine

Clinical Program Development

2014-present *Director*, Clinical Trials Unit, Institute of Human Virology

Clinical/Administrative Service

Institutional Service

2014-present *Associate Chief*, Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine

2014-present *Faculty*, University of Maryland School of Medicine Infectious Diseases Fellowship Program

2014-present *Faculty*, Division of Infectious Diseases, UMD Midtown Campus, Baltimore

2015-present *Faculty*, University of Maryland Medical Schools Admissions Interview Committee

2015-present	<i>Attending Physician</i> , University of Maryland School of Medicine, Division of Infectious Diseases
2015-present	<i>Attending Physician</i> , University of Maryland Midtown Campus, Division of Infectious Diseases
2015-present	<i>Faculty</i> , University of Maryland Graduate School (Microbiology and Immunology)
2015-present	<i>Advisory Committee Member</i> , University of Maryland School of Medicine Medical Scientist Training Program (MSTP)
2015-present	<i>Faculty</i> , University of Maryland Graduate School (Epidemiology and Public Health)
2015-present	<i>Faculty Search Committee Member</i> , Institute of Human Virology and University of Maryland School of Medicine
2015-present	<i>Faculty</i> , Summer Bioscience Internship Program at University of Maryland
2015-present	<i>Member</i> , University of Maryland Medical School Admissions interview Committee
2015-present	<i>Member</i> , University of Maryland School of Medicine Internal Medicine Residency Program Interview Committee
2015-present	<i>Member</i> , University of Maryland School of Medicine Infectious Diseases Fellowship Interview Committee

Local and National Service

Local Service

1999-2000	<i>House Staff Committee</i> , Brown University School of Medicine
2015-2016	<i>Mentoring Committee</i> , American College of Physicians, DC Chapter

National Service

2000-2002	<i>Member</i> , NIAID Fellowship Advisory Committee, NIH
2000-2003	<i>Member</i> , NIH Fellows Committee (FELCOM)
2001-2003	<i>Co-chair</i> , NIH Distinguished Clinical Teacher Sub committee
2001-2003	<i>Member</i> , NIH Medical Executive Committee
2005-2007	<i>Grant Reviewer</i> , Wellcome Trust, London, United Kingdom 2006 The Journal of Infectious Diseases-Editorial Advisory Board
2006	<i>Guest Editor</i> , Hepatology International: Hepatitis Research and Treatment (Special Issue).
2007-2008	<i>Member</i> , NIH Barriers to Clinical Research Committee
2007-2013	<i>Member</i> , NIAID Institutional Review Board
2009-present	<i>Co-chair</i> , NIH-District of Columbia HIV-Hepatitis Consortium
2009-present	<i>Member</i> , Advisory Committee on NIH policy for FDA regulated Research
2009-present	<i>Scientific Director</i> , NIH-District of Columbia Program for AIDS Progress
2009-present	<i>Volunteer ID Physician</i> , Free hepatitis and HIV clinic at Whitman Walker clinic, N.W. Washington DC

2010	<i>Organizer</i> , First NIH-ILBS Symposium on HIV-HCV and Comorbidities, New Delhi, India
2010-2011	<i>Acting Chair</i> , NIAID Institutional Review Board
2010-2013	<i>Member</i> , Medical Advisory Board for NIH-DC Program for AIDS Progress,
2011	<i>Organizer</i> , Tissue Banking Workshop, New Delhi, India
2012-present	<i>Volunteer ID Physician</i> , Free hepatitis and HIV clinic at Family and Medical Counseling Services, Anacostia S.E. Washington DC
2012-present	<i>Grant Reviewer</i> , Canadian Institutes of Health Research (CIHR)
2012-present	<i>Core Faculty</i> , International Antiviral Society (IAS), USA
2012-present	<i>Grant reviewer</i> , DC-Center for AIDS Research (DC-CFAR)
2013- 2013	<i>Chair</i> , HCV Symposium Conference on Retroviruses and Opportunistic Infections
2013-present	<i>Expert Panel Member</i> , IDSA-AASLD Joint Panel on HCV treatment Recommendations
2014-2014	<i>Chair</i> , HCV Therapy, The Liver Meeting
2015-present	<i>Member</i> , National Viral Hepatitis Working Group on Development of Treatment Guidelines for Hepatitis for the Government of Rwanda
2015-2015	<i>Organizing Committee Member</i> , 17 th Annual IHV Meeting, Baltimore MD
2015-2016	<i>Co-Chair</i> , Organizing Committee for IHV-GWU Joint Workshop in HIV infection
2015-present	<i>Mentor</i> , Mentoring Committee for Infectious Diseases Fellows, ID Week

International Service

2012-present	<i>Visiting professor</i> , Institute of Liver and Biliary Sciences, New Delhi, India
2015-present	<i>Visiting faculty</i> , Indian Institute of Liver and Digestive Sciences, Kolkata, India
2015-present	<i>Member</i> , National Viral Hepatitis Working Group on Development of Treatment Guidelines for Hepatitis for the Government of Rwanda

Teaching Service

2002-present	Attending Physician/Staff Clinician Outpatient Clinic and Laboratory Summer Research Training Program, National Institutes of Health 35 undergraduates, 8 hours/day for 3 months/year
2003-present	Attending Physician/Staff Clinician Outpatient Clinic and Inpatient Service University of Maryland Institute of Human Virology and National Institutes of Health 17 Residents/Fellows, 8 hours/day, 2-8 weeks/year
2007-present	Attending Physician/Staff Clinician Outpatient Clinic and Laboratory

University of Maryland Institute of Human Virology and National
Institutes of Health
6 Medical Students; 1 hour/quarterly for 12 months

2007-present Attending Physician/Staff Clinician
Outpatient Clinic and Laboratory
University of Maryland, Institute of Human Virology and National
Institutes of Health
13 Post-Graduates, 1 hour/month, 12 months

2014-present Attending Physician
Clinical Research Trials Unit
University of Maryland, Institute of Human Virology
12 Assistant Professors, 4 hours/month, 12 months

Grant Support

Active Grants

11/1/2014-10/31/2017 Co-Investigator, 5%; PI: Peter Stock, University of San Francisco
A Pilot Study to Assess Safety, Tolerability, and Efficacy of
Sofosbuvir and Ledipasvir for Hepatitis C Treatment in HIV/HCV
Coinfected Subjects Pre or Post Liver Transplant (STOP-CO)
NIH/NIAID-Division of AIDS P0500506, U Grant
Total Direct Costs: \$312,413
Role: Site PI and bench-work PI

11/1/2014-10/31/2017 Co-Investigator, 5%; PI: Ken Sherman, University of Cincinnati
Antiretroviral Toxicity in HIV/HCV infection
NIH/NIAID, RO-1 Grant 2R01AI065256 - 06A1
Total Direct Costs: \$223,962
Role: Mechanistic studies of the grant

11/1/2014-10/31/2017 Co-Investigator, 5%; PI: Ken Sherman, University of Cincinnati
Title: Hepatitis E in HIV-infected Patients
NIH/NIDDK, RO-1DK108362 Grant
Total Direct Costs: \$137,961
Role: Provide HIV patients cohort for testing

01/01/2015-12/31/2017 Principal Investigator
Phase IV Pilot Study to Assess Community-based Treatment
Efficacy in Chronic Hepatitis C Monoinfection and Coinfection
with HIV in the District of Columbia (ASCEND)
Gilead Sciences, Inc. Investigator Initiated Grant
Total Direct Costs: \$1,076,750

09/15/2015-12/31/2016 Principal Investigator

A Prospective Study to Determine Immunophenotypes and Cellular Responses in the Setting of Hepatitis B Infection
Medimmune, Inc., Investigator Initiated Grant
Total Direct Costs: \$400,000

03/01/2016-04/30/2017 Principal Investigator
IHV-Rwanda Hepatitis C Education Collaboration (IRCEC) for HCV provider Training
Gilead Sciences, Inc., Investigator Initiated Grant
Total Direct Costs: \$165,000

05/01/2016-04/30/2018 Principal Investigator
Tenofovir Alafenamide for HBV – A Longitudinal Study (TEMUL)
Gilead Sciences, Inc., Investigator Initiated Grant
Total Direct Costs: \$645,970

05/01/2016-04/30/2018 Principal Investigator
A Pilot Study to Evaluate a Salvage Therapeutic Regimen for HCV Patients Previously Failed Directly Acting Antiviral Therapy (RESOLVE)
Gilead Sciences, Inc., Investigator Initiated Grant
Total Direct Costs: \$3,000,000

07/01/2016-06/30/2017 Principal Investigator
A Novel Model of Hepatitis C Treatment As Anchor to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior (ANCHOR)
Gilead Sciences, Inc., Investigator Initiated Grant:
Total Direct Costs: \$390,543

07/01/2016-06/30/2017 Principal Investigator
Prospective Study to Determine Immunophenotypes and Humoral Responses in the Setting of Chronic Hepatitis B Infection
Arbutus Pharmaceuticals, Investigator Initiated Grant
Total Direct Costs: \$206,000

07/01/2016-06/30/2017 Principal Investigator
Geomapping Resistance and Viral Transmission in Risky Populations (GRAVITY)
Gilead Sciences, Inc., Investigator Initiated Grant
Total Direct Costs: \$456,660

07/01/2016-06/30/2017 Principal Investigator
Geomapping Resistance and Viral Transmission in Risky Populations (GRAVITY-FOCUS)
Gilead Sciences, Inc, FOCUS Program Grant
Total Direct Costs: \$199,000

07/01/16-06/30/17	Principal Investigator Community-based Hepatitis B, C and HIV Education, Screening and Linkage in New Patient Populations (TIGER-FOCUS) Gilead Sciences, Inc, FOCUS Program Grant Total Direct Costs: \$160,000
9/29/16-9/28/17	Principal Investigator NIH Contract for District of Columbia Program for AIDS Progress NIH Office of AIDS Research/CCMD/CC/NIH HHSN269201400012C, Contract Total Direct Costs: \$2,208,243
9/29/17-9/28/22	Principal Investigator NIH Contract for District of Columbia Program for AIDS Progress NIH Office of AIDS Research/CCMD/CC/NIH HHS, Contract (pending) Total Direct Costs: \$9,807,675
01/15/17-12/31/17	Principal Investigator HCV Training Grant-IMPHAL, India The Global Virus Network initiative Gilead Sciences Grants Total direct costs: \$148,487
01/15/17-12/31/17	Principal Investigator HBV Screening Study-Tezpur, India The Global Virus Network initiative John C Martin Foundation Grant Total direct costs: \$218,654
03/12/17-03/11/18	Principal Investigator Immune Correlates of HBV infection Gilead Sciences Inc Total direct costs: \$202,897
06/24/17-06/23/18	Principal Investigator Evaluation of immune correlates of Phase Ia TLR8 Study Gilead Sciences Inc Total direct costs: \$342,347
07/07/17-07/06/18	Principal Investigator Evaluation of immune correlates of Phase 1b TLR8 Study Gilead Sciences Inc Total direct costs: \$436,600
03/12/17-03/11/18	Principal Investigator Truculture Methodology to Evaluate ex vivo immune responses

	Gilead Sciences Inc Total direct costs: \$77,449
04/15/17-04/14/19	Principal Investigator Impact of Immune Suppression on HCV treatment response Merck Inc (MISP) Total direct costs: #245,234
04/01/2017-03/31/2019	Principal Investigator A Novel Model of Hepatitis C Treatment As Anchor to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior (ANCHOR 2) Merck Inc (MISP) Total Direct Costs: \$126,235
08/10/17-08/09/19	Principal Investigator A single site open label study to evaluate the safety and efficacy of grazoprevir/elbasvir for Egyptian patients with hepatitis C genotype 4 infection and advanced renal impairment Merck Inc (MISP) Total direct costs: 399,713
08/15/17-08/14/22	Principal Investigator Immune Correlates of acquisition of HCV infection NIH/NIDA 1R01DA043396 - 01A1, Total Direct Costs: \$1,248,633 Total costs: 1,916,652
09/01/17-09/01/19	Principal Investigator An omnibus clinical protocol to evaluate hepatitis B infection Roche Inc Study support includes HBsAg kits Total direct costs: \$73,267

Active Clinical Trials

2007-present	Principal Investigator of NIIAD Clinical Trial Protocol #07-I-N135 titled "Analysis of stored samples obtained from previously terminated protocols" Co-investigator since 9/15/2014
2010-present	Associate Investigator of NIAID Clinical Trial Protocol #11-I-0157 titled "Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia"
2010-present	Principal Investigator of NIAID Clinical Trial Protocol #11-CC-0152, a Natural history study, titled "HIV-Liver Disease Natural History Prospective Cohort" Co-investigator since 9/15/2014

- 2010-present Associate Investigator of NIAID Clinical Trial Protocol #11-I-0057 titled “Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy”
- 2011-present Associate Investigator of NIAID Clinical Trial Protocol #12-CC-0186 titled “A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- infected Subjects with Liver Fibrosis”
- 2013-present Associate Investigator of NIAID Clinical Trial Protocol #13-I-0140 titled “A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection”
- 2015- present Principal Investigator of Clinical Trial # NCT01667081, Merck Sharp & Dohme Corp named “Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir” (MK-5172) (MK-5172-017)
- 2015- present Principal Investigator of Clinical Trial # NCT02487012, Gilead Sciences, Inc. named “A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection” (ASTRAL-5)
- 2015-present Sub-Investigator of Clinical Trial # NCT02533934, University of California, San Francisco named “Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant” (STOP-CO)
- 2015-present Principal Investigator of Clinical Trial # NCT02607800, Gilead Sciences, Inc. named “Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy” (POLARIS-1)
- 2015-present Principal Investigator of Clinical Trial # NCT02639338, Gilead Sciences, Inc. named “Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis” (POLARIS-2)
- 2015-present Principal Investigator of Clinical Trial # NCT02639247, Gilead Sciences, Inc. named “Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor” (POLARIS-4)
- 2016-present Co-investigator for Clinical Trial named “Safety and Efficacy of Sofosbuvir, Velpatasvir and GS-9857 in Patients who Previously Failed DAA Therapy” (RESOLVE)
- 2017-present Principal investigator for “A pilot Study for HARVONI for HBV

Infection” (APOSTLE)

Completed Grants at University of Maryland

- 9/29/14-9/28/15 Principal Investigator
 NIH Contract for District of Columbia Program for AIDS Progress
 Office of AIDS Research/CCMD/CC/NIH HHSN269201400012C
 Annual Direct Costs: \$739,623
 Total Direct Costs: \$931,926
- 9/29/15-9/28/16 Principal Investigator
 NIH Contract for District of Columbia Program for AIDS Progress
 Office of AIDS Research/CCMD/CC/NIH HHSN269201400012C
 Annual Direct Costs: \$1,014,000
 Total Direct Costs: \$1,277,640

Completed Grants at National Institutes of Health

- 7/1/2001-9/14/2014 Principal Investigator
 #AI000886 titled “Role of Innate Immunity in the Initiation and
 Pathogenesis of HIV infection”
 NIAID Intramural Award
 Annual Budget: \$90,000
 Total Budget: \$1,170,000
- 7/1/2001-9/14/2014 Principal Investigator
 # AI000390 titled “The Therapeutic Strategies for the Management of
 HIV/HCV Co-infection”
 NIAID Intramural Award
 Annual Budget: \$40,000
 Total Budget: \$520,000
- 7/1/2001-9/14/2014 Collaborating Investigator (Co-Inv, PI, Dr. Tae-Wook Chun Ph.D)
 #AI000885 titled “Immunologic and Virologic Strategies Directed toward
 HIV infection”
 NIAID Intramural Award
- 7/1/2001-9/14/2014 Collaborating Investigator (PI: Dr. Sharon Wahl Ph.D)
 #DE000513 titled “Role of Monocytes in AIDS and as Targets of Antiviral
 Therapy”
 NIDCR Intramural Award
- 7/1/2001-9/14/2014 Collaborating Investigator (PI: Dr. Susan Moir Ph.D)
 #AI000825 titled “Role of B lymphocytes in HIV infection and
 Pathogenesis”
 NIAID Intramural Award
- 7/1/2001-9/14/2014 Collaborating Investigator (PI: Dr. Frank Maldarelli MD, Ph.D)

- # BC010527 titled “Characterization of the Genetic Diversity of HIV-1 in Infected Individuals”
NCI Intramural Award
- 7/1/2001-9/14/2014 Collaborating Investigator (PI: Dr. Frank Maldarelli MD, Ph.D)
BC010528 titled “In Vivo assessment of Residual Drug Activity in Patients with Genotypic and Phenotypic resistance”
NCI Intramural Award
- 7/1/2001-9/14/2010 Collaborating Investigator
#BC010819 titled “HIV Genetic Variation Infected individuals”
NIAID
- 7/1/2003-9/14/2014 Collaborating Investigator (PI: Dr. David Kleiner MD, Ph.D)
ZIC010687 titled “Hepatic Histology Core Laboratory Research”
NCI Intramural Award
- 10/1/2005-9/30/2007 Collaborating Investigator
Persistent HIV Reservoirs in Infected Patients Receiving Effective Antiviral Therapy for Prolonged Periods of Time: Delineation of Mechanism and Source of Viral Replication and Execution of a New Therapeutic Strategy
NIH Bench to Bedside
Total budget: \$400,000
- 10/1/2006-9/30/2008 Collaborating Investigator
Genetic Characteristics of HIV-1 during Suppressive Antiretroviral Therapy
NIH Bench to Bedside
Total budget: \$400,000
- 10/1/2006-9/30/2008 Collaborating Investigator
Intensification of Antiretroviral Therapy Using HIV Integrase Inhibitor (MK-0518) to Assess Decay of Viral Reservoirs in Peripheral Blood and Gut-Associated Lymphoid Tissue of Chronically Infected Patients
NIH Bench to Bedside
Total budget: \$400,000
- 7/1/2007-9/14/2011 Collaborating Investigator
#AI001039 titled Antiviral activities of Human Interferons
NIAID Intramural Award
- 10/1/2007-9/30/2008 Principal Investigator
High-Throughput Serum Protein Analysis to Predict Therapeutic Responses of Chronic Hepatitis C
NIH DIR Supplemental Award
Total budget: \$60,000
- 10/1/2009-9/30/2010 Principal Investigator
Ethnicity on Host Molecular factors that determine HCV Treatment Responses to Peg interferon-alpha and Ribavirin

- Office of AIDS Research Cycle 3 Award
Total budget: \$100,000
- 10/1/2009-9/30/2010 Principal Investigator
Role of IFNAR2a on IFN Non-responsiveness of HIV/HCV-infected African Americans
Office of AIDS Research Cycle 2 Award
Total budget: \$75,000
- 10/1/2009-9/30/2010 Principal Investigator
Immunoregulation of HBV specific T cell responses in relation to the antiviral effect of HBV therapeutics in HBV mono and HIV/HBV co-infected subjects
NIH DIR Supplemental Award
Total budget: \$70,000
- 10/1/2010-9/30/2011 Principal Investigator
HIV, Hepatitis and Co-morbidities First-NIH Indo International Conference Award
Office of AIDS Research Cycle 3 Award
Total budget: \$90,000
- 10/1/2010-9/30/2011 Principal Investigator
Scientific support for NIH-District of Columbia Program for AIDS Progress (DC-PFAP)
Office of AIDS Research
Total budget: \$100,000
- 10/1/2011-9/30/2012 Principal Investigator
Hepatitis Research in HIV patients
Office of AIDS Research Cycle 3 Award
Total budget: \$100,000
- 10/1/2011-9/30/2012 Principal Investigator
Scientific support for NIH-District of Columbia Program for AIDS Progress (DC-PFAP)
Office of AIDS Research Cycle 3 Award
Total budget: \$125,000
- 10/1/2011-9/30/2013 Principal Investigator
Effect of CCR5 Blockade on liver disease progression in HIV infected subjects
NIH Bench to Bedside
Total budget: \$470,000
- 10/1/2012-9/30/2013 Principal Investigator
Scientific support for NIH-District of Columbia Program for AIDS Progress (DC-PFAP)
Office Of AIDS Research
Total budget: \$135,000

- 10/1/2012-9/30/2014 Co-Principal Investigator (Co-PI: Dr. Caryn Morse MD)
Effect of Lysyl Oxidase-2 inhibition on progression of liver fibrosis”
NIH Bench to Bedside Award
Annual Budget: \$235,000
Total budget: \$470,000
- 10/1/2012-9/30/2014 Principal Investigator
Programmed Death Receptor- Blockade to treat chronic hepatitis B in HIV
infection
NIH Bench to Bedside Award
Annual Budget: \$235,000
Total Budget: \$470,000
- 10/1/2012-9/30/2014 Collaborating Investigator (PI: Colleen Hadigan MD)
Development of Magnetic resonance Spectroscopy to Assess Liver Fat
Content
NIH Bench to Bedside Award
Annual Budget: \$235,000
Total Budget: \$470,000
- 1/1/2013-9/14/2014 Principal Investigator
Treatment of HIV/HCV Coinfected Subjects with Fixed Dose Combination
CRADA with Gilead Sciences, Inc.
Total Budget: \$501,000
- 1/1/2013-9/14/2014 Principal Investigator
Treatment of HCV infection using multiple combinations of Directly
Acting Agents
CRADA with Gilead Sciences, Inc.
Total Budget: \$300,000
- 10/1/2013-9/30/2014 Principal Investigator
Scientific support for NIH-District of Columbia Program for AIDS
Progress (DC-PFAP)
Office Of AIDS Research
Total Budget: \$125,000

Completed Clinical Trials

- 2001-2012 Principal Investigator of NIAID Clinical Trial Protocol #02-I-0202 titled
“Leukapheresis Procedures to Obtain Plasma and Lymphocytes for
Research Studies on Antiretroviral naïve Primary and Chronic HIV-
Infected individuals”
- 2001-2006 Principal Investigator of NIAID Clinical Trial Protocol #01-I-0194, Phase
III study, titled “A Non-Randomized, Open label, Study to Assess Hepatitis
C Kinetics in Predicting the Clinical Response in Patients with Hepatitis C

- infection Co-infected with HIV-1 Treated with Peginterferon Alpha-2b and Ribavirin”
- 2001-2003 Principal Investigator of NIAID Clinical Trial Protocol #02-I-0139, a Phase III study, titled “A Randomized, Controlled Study to Assess the Impact of Highly Active Antiretroviral Therapy to Hepatitis C Therapy in Patients Co-infected with HIV-1 and Treated with Peginterferon Alpha-2b and Ribavirin”
- 2002-2006 Associate Investigator of NIAID Clinical Trial Protocol #03-I-0310 titled “Immune Response to Influenza Vaccination in HIV-infected Individuals”
- 2002-2006 Associate Investigator of NIAID Clinical Trial Protocol #02-I-0013 titled “A Randomized, Controlled Trial of Short Cycle Intermittent Versus Continuous HAART for the Treatment of Chronic HIV Infection”
- 2002-2006 Associate Investigator of NIAID Clinical Trial Protocol #00-I-0020 titled “Immunologic and Virologic Studies of Intermittent versus Continuous HAART in the Treatment of HIV Disease”
- 2003-2013 Principal Investigator of NIAID Clinical Trial Protocol #92-I-0125 titled “Analysis of Peripheral Blood Versus Lymphoid Tissue among HIV-Infected and Normal Patients”
- 2003-2014 Principal Investigator of NIAID Clinical Trial Protocol #91-I-0140 titled “Studies of the Pathogenesis of HIV infection in Human Peripheral Blood Cells and/or Reproductive Fluids in HIV-infected and HIV-uninfected Volunteers”
- 2003-2015 Principal Investigator of NIAID Clinical Trial Protocol #04-I-0086 titled “Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on HCV-infected Patients”
- 2003-2005 Principal Investigator of NIAID Clinical Trial Protocol #04-I-0149, a Phase I study, titled “An Open label Trial to Assess the Safety and Tolerability of Daclizumab in HIV-infected Individuals”
- 2003-2007 Principal Investigator of NIAID Clinical Trial Protocol #04-I-0187, a Phase II study, titled “A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Twice-Weekly Peginterferon Alpha 2a and Ribavirin Induction Therapy for Chronic Hepatitis C in Patients who are Coinfected with HIV-1”
- 2003-2005 Principal Investigator of NIAID Clinical Trial Protocol #04-I-0097, a Phase II study, titled “A Randomized Controlled Study to Evaluate the Safety and Efficacy of Long-Term Peginterferon Alpha 2a for Treatment of Chronic Hepatitis C Patients Coinfected with HIV-1”
- 2007-2011 Principal Investigator, Clinical Trials Agreement with Human Genome Sciences Inc. Albinferon for HIV/HCV Coinfected Subjects
- 2007-2010 Principal Investigator of NIAID Clinical Trial Protocol #07-I-0001, a Phase I study, titled “An Open label Trial to Assess the Safety and Tolerability of

- Albuferon 1800mcg every two weeks along with ribavirin in HCV/HIV-infected Individuals”
- 2007-2010 Associate Investigator of NIAID Clinical Trial Protocol #08-I-0034 titled “Validation of (1)H-Magnetic Resonance Spectroscopy for Quantification of Hepatic Triglyceride Content”
- 2009-2012 Principal Investigator of NIAID Clinical Trial Protocol #10-I-N184, a Natural history study, titled “Liver Fibrosis Progression in African Americans with HIV-HCV Co-Infection”
- 2009-2012 Principal Investigator of NIAID Clinical Trial Protocol #10-I-0159, a Phase I study, titled “An Open Label Study to Evaluate the Safety, Efficacy, Viral Kinetics Genetic, Epigenetic, and Proteomic Expression of Weekly Peg interferon Alpha 2a and Ribavirin Therapy for Chronic Hepatitis C in Latino Subjects with and without HIV Coinfection”
- 2009-2012 Principal Investigator of NIAID Clinical Trial Protocol #10-CC-0183, a Phase I study, titled “An Open label Trial to Assess the Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders”
- 2010-2011 Principal Investigator, Clinical Trials Agreement with Pharmasset Inc. PSI 7977 with ribavirin to treat hepatitis C genotype 1 infected subjects
- 2011-2012 Associate investigator of NIAID Clinical Trial Protocol #12-I-0173 titled “A Long Term Follow-up Registry of Subjects Who Did Not Achieve Loss of S Antigen (HBsAg) and Sustained HBV Viral Load Reduction Below the Limit of Quantitation (BLQ) in Gilead-Sponsored Trials of GS-9620 in Subjects with Chronic Hepatitis B Infection”
- 2011-2012 Associate investigator of NIAID Clinical Trial Protocol #12-I-0172 titled “Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects with Chronic Hepatitis B Virus Infection”
- 2011-2012 Associate investigator of NIAID Clinical Trial Protocol #12-I-0171 titled “Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Naive Subjects with Chronic Hepatitis B Virus Infection”
- 2011-2012 Associate investigator of NIAID Clinical Trial Protocol #12-I-0115 titled “Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in naive Subjects with Chronic Hepatitis C Virus Infection”
- 2011-2013 Principal Investigator, Clinical Trials Agreement with Gilead Sciences Inc. TLR-7 agonist to treat chronic hepatitis C patients.

- 2011-2013 Principal Investigator, Clinical Trials Agreement with Gilead Sciences Inc. TLR-7 agonist to treat chronic hepatitis B treatment experienced patients.
- 2011-2013 Principal Investigator, Clinical Trials Agreement with Gilead Sciences Inc. TLR-7 agonist to treat chronic hepatitis B treatment naive patients.
- 2011-2014 Principal Investigator, Clinical Trials Agreement with Merck Inc. Peg interferon alfa, ribavirin and boceprevir for treating HIV/HCV coinfecting subjects
- 2011-2014 Principal Investigator of NIAID Clinical Trial Protocol #11-I-0258, a Phase II study, titled “A Randomized Controlled Study to Assess Safety, Tolerability and Efficacy of PSI-7977 alone or in combination with RBV in HCV Genotype 1-infected Treatment Naive Patients”
- 2011-2013 Principal Investigator of NIAID Clinical Trial Protocol #11-CC-0253, a Phase III study, titled “An Open Label, On-Treatment Trial, to Assess the Effect of HIV Coinfection on Therapeutic Responses using Boceprevir, Peg-Interferon-alfa 2b and Ribavirin in HCV Genotype 1a Treatment Naive Subjects”
- 2012-2014 Principal Investigator, Clinical Trials Agreement with Gilead Sciences Inc. Anti-LOXL2 to treat chronic liver fibrosis patients
- 2012-2014 Principal Investigator, Corporate Research and Development Agreement with Gilead Sciences Inc. Evaluation of multiple combination therapy to treat chronic hepatitis C patients
- 2012-2014 Principal Investigator, Corporate Research and Development Agreement with Gilead Sciences Inc. Combination therapy to treat chronic hepatitis C patients in HIV-infected subjects
- 2012-2014 Principal Investigator of NIAID Clinical Trial Protocol #14-I-0157, a Phase II study, titled “An open label Trial to Assess Safety, Tolerability and Efficacy of GS-7977 in combination with GS-5885 in HIV/HCV Genotype 1-infected Treatment naive patients”.
- 2012-2016 Principal Investigator of NIAID Clinical Trial Protocol #13-I-0066, a Phase II study, titled “A pilot study to evaluate the safety and efficacy of multiple anti-HCV combination therapy in chronically infected hepatitis C genotype 1 subjects who are naïve or null responders to peg-interferon alpha based therapy” Co-investigator since 9/15/2014
- 2013-2014 Principal Investigator, Clinical Trials Agreement with Bristol Myers Squibb Inc. Asunaprevir with Daclatasvir for treatment of hepatitis C in HIV infected subjects

Publications

Peer-reviewed Journal Articles

1. Suresh K, Jayavardhanan KK, **Kottilil S**, Kuttappan C, and Vasudevan DM. Natural Killer Cell and Antibody Dependent Cellular Cytotoxicity in Gastric Carcinoma Patients: *Oncology Reports*. (1994), 1: 439.
2. Kutty KM, **Kottilil S**, and Andrews W. From Pseudocholinesterase to AIDS virus: *Medical Hypothesis* (1995), 45: 225.
3. **Kottilil S**, Gallant M, and Grant M. A Novel Mechanism of Activation-Induced Lymphocyte Death Related to HIV infection: *Mol. Biol. Cell*. (1996), 7:144a.
4. Marshall T, **Kottilil S**, Bowmer I, Trahey J, Pardoe I, and Grant MD. Characterization of Autoreactive Cytotoxic T Lymphocytes in HIV-infected individuals. *Can J. Infect. Dis* (1997), 8S: 62A.
5. **Kottilil S**, Bowmer I, Trahey J, Campbell C, Gallant M, and Grant MD. The Relationship Between Circulating Autoreactive Cytotoxic T Lymphocytes Activity and Stage of Disease in HIV infection. *Can J. Infect. Dis*. (1997), 8S: 62A.
6. Grant MD, **Kottilil S**, Marshall T, Gallant M, Pardoe I, Trahey J, Campbell C, and Bowmer I. Phenotypic, Functional and Molecular Genetic Changes in the CD8⁺ T cell population in HIV infection. *Immunol Lett*. (1997), 56:362.
7. Hamdalla H, **Kottilil S**, and Fram R. The Limitations of Bone Scan vs. MRI for bone metastases. *Med Health R.I.* (2000), 83: 297.
8. **Kottilil S**, Fram R, Schwartz S, Cortez KJ and Kesan S. Hypercalcemia and T-cell lymphoma with acquired immunodeficiency syndrome: Occurrence without human T-cell leukemia virus-I. *South Med. J* (2000), 93:894-897.
9. **Kottilil S**, Gamberg J, Bowmer I, Trahey J, Howley C, Gallant M, and Grant MD. Human Immunodeficiency Virus type-1 Replication, Immune activation and Circulating Cytotoxic T lymphocytes Against CD4⁺ T cells. *Grant. J. Clin. Immunol.* (2000), 23:175-186.
10. Papudesu B, Menon M, Yunis N, and **Kottilil. S**. Invasive Pneumococcal disease. *Med Health R.I.* (2001), 84:89-91.
11. **Kottilil S**, Bowmer MI, Trahey J, Howley JC, Gamberg J, and Grant MD. Fas/FasL-independent activation-induced cell death of T lymphocytes from HIV-Infected individuals occurs without DNA fragmentation. *Cell Immunol.* (2001), 214 :1-11.
12. Palmer S, Kearney M, Maldarelli F, **Kottilil S**, Lucey D, Metcalf J, Rock D, VanHoutte M, Michels L, Hertogs K, Mellors J, and Coffin J. Genetics of HIV-1 populations in acute and chronic infection. *Antiviral Ther.* (2002), 7:S57.
13. **Kottilil S**. NK cells in HIV-1 Infection: Role of NK cell-mediated non-cytolytic mechanisms in pathogenesis of HIV-1 infection. *Ind. J. Exp Biol.* (2003), 41:1219-1225.
14. **Kottilil S**, Malech HL, Gill VJ, and Holland SM Infections with *Haemophilus Species* in Chronic Granulomatous Disease: Codependence of bacterial Catalase and Hydrogen Peroxide Production. *Clin immunol* (2003), 106:226-30.
15. Cortez KJ, **Kottilil S**, and Mermel L. Intracerebral tuberculomas misdiagnosed as neurosarcoidosis. *South. Med J.* (2003), 96:494-496.
16. **Kottilil S**, Chun TW, Moir S, Liu S, McLaughlin M, Hallahan CW, Maldarelli F, Corey L, and Fauci AS. Innate Immunity in HIV Infection: Effect of Viremia on NK Cell Function. *J. Infect Dis* (2003), 187:1038-45.

17. Moir S, Ogwaro KM, Malaspina A, Vasquez J, Donoghue ET, Hallahan CW, Liu S, Ehler LA, Planta MA, **Kottlil S**, Chun TW, and Fauci AS. Perturbations in B cell responsiveness to CD4 T cell help in HIV-infected Individuals. *Proc. Natl. Acad. Sci. USA* (2003), 100:6057-62.
18. Malaspina A, Moir S, **Kottlil S**, Hallahan CW, Ehler LA, Liu S, Planta MA, Chun TW, Fauci AS. Deleterious Effect of HIV-1 Plasma Viremia on B Cell Costimulatory Function. *J Immunol.* (2003), 170:5965-72.
19. Moir S, Donoghue ET, Pickeral OK, Malaspina A, Planta MA, Chun TW, Krishnan SR, **Kottlil S**, Birse CE, Leitman SF, and Fauci AS. Continuous flow leukapheresis induces expression of stress genes in lymphocytes; impact on microarray analyses. *BLOOD* (2003), 102:3852-3.
20. Mavilio D, Benjamin J, Daucher M, Lombardo G, **Kottlil S**, Planta MA, Marcenaro E, Bottino C, Moretta L, Moretta A, and Fauci AS. Natural Killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. *Proc Natl Acad Sci, USA* (2003), 100:15011-15016.
21. **Kottlil S**, Jagannatha S, Lu A, Liu S, McLaughlin M, Metcalf JA, Dewar R, Ternisky C, Koratich C, Maldarelli F, Masur H, and Polis MA. Changes in Hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. *HIV Clin Trials* (2004), 5:25-32.
22. Chun TW, Justement JS, Sanford C, Hallahan CW, Planta MA, Loutfy M, **Kottlil S**, Moir S, Kovacs C, and Fauci AS Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals. *Proc Natl Acad Sci USA.* (2004), 101 8:2464-9.
23. **Kottlil S**, Polis MA, Kovacs JA. HIV Infection, Hepatitis C infection, and HAART: Hard Clinical Choices. *JAMA.* (2004), 292:243-50.
24. **Kottlil S**, Shin K., Planta M, McLaughlin M, Hallahan CW, Ghany M, Chun TW, Sneller MC, and Fauci AS Expression of chemokine and inhibitory receptors on NK cells: Effect of immune activation and HIV viremia. *J. Infect Dis.* (2004), 189:1193-1198.
25. Farel C, Suzman DL, McLaughlin M, Campbell C, Koratich C, Metcalf JA, Masur H, Robinson MR, Polis MA and **Kottlil. S**. Serious Ophthalmic Pathology Compromising Vision in HCV/HIV Coinfected Individuals Treated With Peginterferon Alpha 2b and Ribavirin. *AIDS* (2004), 18:1804-1809.
26. Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ, Krishnan SR, Planta MA, Turney JF, Justement JS, **Kottlil S**, Dybul M, Mican JM, Kovacs C, Chun TW, Birse CE, and Fauci AS. Survival of B Cells of HIV-viremic Patients Mediated by Altered Expression of Receptors of the TNF Super family. *J Exp Med.* (2004), 200:587-99.
27. Malaspina A, Moir S, Orsega S, Vasquez J, Miller NM, Donoghue ET, **Kottlil S**, Gezmus M, Follman D, Vodeiko GM, Levandowski RA, Mican JM, and Fauci AS. Compromised B cell responses to influenza vaccine in HIV-infected individuals. *J Infect Dis.* (2005), 191:1442-50.
28. Gupta N, Steenebeke T, Khazanie P, Chung E, Cruz C, Censoplano N, Van Ryk D, Schuck P, Sun P, Raedev S, Daucher M, **Kotillil S**, Mavillio D, Chaikin M, Rabin R, Cicala C, Arthos J, and Fauci AS. Biological and Biochemical Characterization of a Highly Polymerized CD4-Ig Fusion Protein that Mediates Efficient Antibody Dependent Cell Mediated Cytotoxicity Against HIV Infected Cells. *Virology* (2005), 332:491-7.
29. **Kottlil S**, Jackson JO and Polis MA. Hepatitis B and C coinfection in HIV-infected

- individuals. *Ind J Med Res.* (2005), 121: 424-50.
30. Fauci AS, Mavilio D, and **Kottlilil S**. NK cells in HIV infection: Paradigm for Protection or Targets for Ambush. *Nat Rev Immunol.* (2005), 5: 835-43.
 31. Walsh TJ, Rollides E, Cortez K, **Kottlilil S**, Bailey J, and Lyman C. Control, Immunoregulation, and Expression of Innate Pulmonary Host Defenses Against *Aspergillus fumigatus*. *Medical Mycology* (2005), 43:S165-72.
 32. Cortez K, Lyman CA, Kim HS, Rollides E, Yang, J, Lempicki R, **Kottlilil S**, and Walsh TJ. Kinetics of gene expression of innate host defense molecules in human monocytes infected with *Aspergillus fumigatus*. *Infect Immun* (2006), 74:2353-65.
 33. Pau A., McLaughlin M, Hu, Z., Polis MA, **Kottlilil S**. Predictors of Hematopoietic Growth Factors Use in HIV/HCV Co-infected Patients Treated With Peginterferon Alpha 2b and Ribavirin. *AIDS Patient Care and STDs.* (2006), 20: 612-619.
 34. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, Wu L, Rehm CA, Masur H, Lane HC, Sherman KE, Fauci AS, and **Kottlilil S**. Gene expression profiles in HCV/HIV coinfection: Class prediction analyses prior to treatment predicts outcome of HCV therapy among HIV coinfecting individuals. *J. Infect Dis.* (2006), 193: 1172-7.
 35. **Kottlilil S**, Shin K, Jackson JO, Reitano K, O'Shea MA, Yang J, Hallahan CW, Lempicki R, Arthos J, and Fauci AS. Innate immune dysfunction in HIV infection: Effect of HIV envelope-NK interactions. *J Immunol.* (2006), 176: 1107-14.
 36. **Kottlilil S**, Wu L., Lempicki RA, Yang J, McLaughlin M, Hu Z, Koratich C, Reitano KN, Rehm C, Masur H, Wood B, Kleiner DE, and Polis MA. Hepatic histologic response (HR) to combination therapy among HCV/HIV coinfecting individuals: Interferon-induced HR independent of Sustained Virologic Response (SVR). *AIDS Res Hum Retrovir.* (2006), 22: 1091-8.
 37. Malaspina A, Moir S, Rehm CA, **Kottlilil S**, Chaitt D, Falloon J, and Fauci AS. Idiopathic CD4⁺ T Lymphocytopenia is Associated with Increases in Immature/Transitional B Cells and Serum Levels of IL-7. *Blood.* (2007), 109:2086-8.
 38. Myers JH, Justement JS, Hallahan CW, Blair ET, Sun YA, O'Shea MA, Roby G, **Kottlilil S**, Moir S, Kovacs C, Chun T-W, and Fauci AS. Impact of HIV on Cell Survival and Antiviral Activity of Plasmacytoid Dendritic Cells. *PLoS One* (2007), 2:458.
 39. Nussenblatt V, McLaughlin M, Rehm C, Lempicki RA, Brann T, Yang J, Proschan M, Imamichi T, Koratich C, Neumann A, Masur H, Polis MA, **Kottlilil S**. Immunodeficiency and Intrinsic IFN Resistance Lead to Viral Breakthrough to HCV Therapy In HIV Coinfecting Patients. *AIDS Res Hum Retrovir.* (2007), 11:1354-9.
 40. **Kottlilil S**, Jackson JO, Reitano KN, O'Shea MA, Roby G, Lloyd M, Yang J, Hallahan CW, Rehm CA, Arthos J, Lempicki RA, and Fauci AS. Innate Immunity in HIV Infection: Enhanced CD95-Mediated NK Cell Death and Turnover Induced by HIV Viremia. *J. AIDS.* (2007), 46:151-159.
 41. Neumann AU, McLaughlin M, Koratich C, Rehm CA, Masur H, Polis MA, **Kottlilil S**. Differential Anti-Viral Effect of Peg-IFN a-2b on HIV and HCV in Treatment of HIV/HCV Co-Infected Patients. *AIDS* (2007), 21: 1855-65.
 42. Highbarger HC, Hu Z, **Kottlilil S**, Metcalf JA, Polis MA, Vasudevachari MB, Lane HC, and Dewar RL. Comparison of the Abbott 7000 and the Bayer 340 systems for the measurement of HCV viral load. *J. Clin Micro.* (2007), 45:2808-12.
 43. Cortez KJ, Rollides E, Quiroz-Telles F, Meletiadis J, Antachapoulos C, Knudsen T, Buchanan W, Milanovich J, Sutton DA, Fothergill A, Rinaldi MG, Shea YR, Zaoutis T,

- Kottlilil S** and Walsh TJ. Infections caused by *Scedosporium* Spp. *Clin Microbiol. Rev* (2008), 21; 157-197.
44. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra T, Conrad TP, Lempicki RA, Cruz C, Censoplano N, Chung E, Reitano KN, **Kottlilil S**, Goode D, Fauci AS. The HIV-1 Envelope Binds to $\alpha 4\beta 7$ integrin, the gut mucosal homing receptor. *Nat Immunol.* (2008), 9:301-309.
 45. Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, Cogliano-Shutta NA, Mican JM, Davey, JT Jr., **Kottlilil S**, Lifson JD, Metcalf JA, Lempicki RA, and Connors M. HIV Viremia Induces Plasmacytoid Dendritic Cell Activation In Vivo and Diminished Interferon- α Production In Vitro. *J Virol* (2008), 82: 3997-4006.
 46. Moir S, Malaspina A, Ho J, DiPoto A, **Kottlilil S**, Roby G, O'Shea A, Mican J, Chun TW, and Fauci AS. Increased B Cells Counts in Chronic HIV Disease during ART Is Associated with Disappearance of Apoptosis-prone B Cell Subsets. *J. Infect Dis* (2008), 197:572-9.
 47. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, **Kottlilil S**, Moir S, Mican JA, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, and Fauci AS. Persistence of HIV in Gut Associated Lymphoid Tissue Despite Long-Term Antiretroviral Therapy. *J. Infect Dis* (2008) 197:714-720.
 48. **Kottlilil S.** and Polis MA. HIV/AIDS Reviews *J. Urban Health* (2008), 1:6-10.
 49. Suzman D, Hoehn G, Munson P, Ying X-A, McLaughlin M, Koratich C, Masur H, Rehm CA, Polis MA, and **Kottlilil S.** Biomarkers as predictors of liver fibrosis in HIV infection. *AIDS* (2008), 22:1432-9.
 50. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, Roby G, **Kottlilil S**, Arthos J, Proschan MA, Chun TW, Fauci AS. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. *J Exp Med.* (2008), 205:1797-805.
 51. Allison RD, Katsounas A, Koxiol DE, Kleiner DE, Lempicki RA, Polis MA, and **Kottlilil S** Interleukin-15 Induced peripheral immune activation is associated with Hepatic Stellate Cell activation in HIV/HCV co-infected individuals. *J Infect Dis* (2009), 200:619-23.
 52. **Kottlilil S.**, Yan MY Reitano KN, Zhang X, Lempicki RA, Roby G, Daucher M, Yang J, Ghany M, Polis MA, and Fauci AS. HIV and HCV infections induce distinct immunologic imprints with implications for the pathogenesis of liver disease and therapeutic response to interferon-alpha. *Hepatology* (2009), 50:34-45.
 53. Osinusi A., Kleiner DE, Wood B, Polis MA, **Kottlilil S.** Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection. *AIDS Patient Care and STDs.* (2009), 23:403-6.
 54. Cortez K, Lyman CA, Kim HS, Rollides E, Yang, J, Lempicki R, **Kottlilil S**, and Walsh TJ. Comparative Genomics of Monocyte Response to *Aspergillus* and *Rhizopus* spp. *Infect Immun.* (2009), 21: 157-97.
 55. Neis-Kraske E, Condoluci D, Schaker TW, Orenstein J, Brenchley J, Fox C, Daucher M, Dewar R, Urban E, Hill B, Guenaga J, Hoover S, Maldarelli F, Hallahan CW, Horn J, **Kottlilil S**, Chun TW, Folino M, Planta MA, Metcalf JA, Douek D, Coffin J, Haase A, Fauci AS and Dybul M. Evaluation of the pathogenesis of declining CD4 T cell counts in HIV-1 infected patients receiving successfully suppressive antiretroviral therapy. *J. Infect Dis.* (2009), 199: 1648-56.

56. Zhang X, Frank AC, Gille CM, Daucher M, Kabat J, Becker S, Lempicki RA, Cortez KJ, Polis MA, Subramanian M, **Kottlil S**. Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to Mapatumumab-induced apoptosis. *Hepatol Res* (2009), 39:1178-89.
57. **Kottlil S.**, Reitano KN, Gille CM, Zhang X, Yan M, O'Shea MA, Roby G, Hallahan CW, Yang J, Lempicki RA, Arthos J and Fauci AS. Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection. *AIDS Res Hum Retr* (2009), 10: 1029-37.
58. Neumann AU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, Buti-Ferret M, Fauci AS, Polis MA, and **Kottlil S**. Hepatitis C viral kinetics during treatment with Peg-IFN-alpha 2b in HIV/HCV co-infected patients as a function of baseline CD4+T cell counts. *JAIDS* (2009), 52:452-8.
59. Rozenberg L., Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA and **Kottlil S**. Therapeutic response to Peg-IFN_alpha-2b and ribavirin in HIV/HCV co-infected African American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. *AIDS* (2009), 23:2439-50.
60. Cicala C, Martinelli E, McNally J, Goode D, Gopaul R, Hiatt J, **Kottlil S.**, Vann RyK D, Fauci AS, and Arthos J. The Integrin $\alpha 4\beta 7$ Forms a Complex with Cell-Surface CD4 and Defines a T Cell Subset that is Highly Susceptible to Infection by HIV-1. *Proc Natl Acad Sci USA*. (2009), 106:20897-82.
61. Frank AC, **Kottlil S.**, Imamichi T. IL-27 mediated suppression of HCV replication in vitro. *J Interferon and Cytokine Research*. (2010), 30: 427-31.
62. Osinusi A, Rasimas JJ, Bishop R, Proschan M, Murphy AA, McLaughlin M, Polis MA, Masur H, Rosenstein D, **Kottlil S**. HIV/HCV co-infected virologic responders to pegylated interferon and ribavirin therapy more frequently incur IFN-related adverse events than non-responders. *J AIDS* (2010), 53:357-63.
63. Broering R, Trippler M, Jiang M, Zhang X, Lu M, Gerken G, **Kottlil S**, and Schlaak JF. The Interferon stimulated gene 15 is a proviral factor for the Hepatitis C virus and an attenuator of the IFN response. *Gut*. (2010), 59: 1111-9.
64. Asmuth DM, Cai T, Chan E, Murphy RL, Schooley RT, Lertora JL, Rinaldo CR, **Kottlil S**, Wahl S, Thielman N, Li X-D, Lempicki RA, Schreiber M, Shore J, Janik J, Simpson Y, Rosenkranz SL, Cramer Y, Pollard RB for the ACTG A5192 Team. Safety, tolerability and mechanisms of antiretroviral activity of Alpha-alpha 2a in HIV-1 infected subjects: A phase II clinical trial. *J. Infect Dis*. (2010), 201: 1686-96.
65. Chary A, Winters MA, **Kottlil S**, Murphy AA, Polis MA, and Holodniy M. Impact of Interferon Ribavirin treatment on Hepatitis C Virus protease quasispecies diversity in HIV/HCV co-infected patients. *J Infect Dis*. (2010), 202: 889-893.
66. Natarajan V, **Kottlil S**, Hazen A, Murphy AA, Adelsberger J, Polis MA and Kovacs JA. HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals. *J Med Virol*. (2010), 82:2032-7.
67. Burbelo PD, Kovacs JA, Ching KH, Issa AT, Iadarola MJ, Murphy AA, Schlaak JF, Masur H, Polis MA and **Kottlil S**. Proteome wide anti-HCV and anti-HIV profiling for predicting and monitoring response to HCV treatment in HIV co-infected patients. *J. Infect Dis* (2010), 202:894-8.
68. Moir, S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, Posada, JG, Kardava L, O'Shea MA, **Kottlil S.**, Chu TW, Proschan M, Fauci AS. B cells in early and chronic HIV

- infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. *Blood*. (2010), 116: 5571-9.
69. Murphy AA, Hermann E, Wu L, Sachau W, O'Shea MA, Yang J, Lempicki RA, Proschan M, Masur H, Haagmans BL, **Kottilil S** and Polis MA. Twice Weekly Peg IFN-alpha-2a and Ribavirin results in superior viral kinetic response in HIV/HCV Co-infected African American Patients Compared to Standard Treatment. *AIDS* (2011), 25:1179-1187.
 70. Burbelo PD, Bren KE, Ching KH, Gogineni ES, **Kottilil S**, Cohen JI, Kovacs J and Iadarola MJ. LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV. *Molecular Biosystems* (2011), 7:1453-62.
 71. Sidique N, Shivakumar B, Polis MA, Masur H, **Kottilil S**. Similar Early HCV Kinetics and Therapeutic Response to HCV Therapy among Long Term Non-Progressors and Chronic HIV infected Subjects. *J. AIDS* (2011), 58:e38-40.
 72. Katsounas A, Trippler M, Wang B, Lempicki RA, Polis MA, **Kottilil S**, Gerken G, Schlaak JF Heat Shock 22kDa Protein 8 (HSPB8) induced Peripheral Toll-like-Receptor (TLR) 4-dependent Immune Activation is associated with Severe Hepatic Fibrosis in Chronic Hepatitis C Virus infection (cHCV). *J Infect Dis* (2011), 8:1181-5.
 73. Shah SR, Patel K, Marcellin P, Foster GR, Manns M, **Kottilil S**, Healey L, Pulksteni E, Subramanian GM, McHutchison J, Sulkowski M., and Nelson DR. Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Hepatitis C Virus Genotype 3. *Clin Gastro Hepatol* (2011), 9:688-93.
 74. Trehanpati N, **Kottilil S**, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK. J. Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate. *J. Clin Immunol.* (2011), 31:509-20.
 75. Jones DM, Atoom AM, Zhang X, **Kottilil S**, Russell RS. A Genetic Interaction Between the Core and NS3 Proteins of Hepatitis C Virus is Essential for Production of Infectious Virus. *J Virol.* (2011), 85:12351-61.
 76. Hubbard J, **Kottilil S**. Extra-hepatic replication of the hepatitis C virus: current issues and future directions. *Future Virology* (2011), 6: 275-278.
 77. Hadigan C and **Kottilil S**. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. *JAMA* (2011), 306:294-301.
 78. Rasimas JJ, Katsounas A, Raza H., Rosenstein D, McLaughlin M, Sachau W, O'Shea MA, Masur H, Murphy AA, Lempicki RA, Polis MA, **Kottilil S**. Class Prediction Analyses of Gene Expression Profiles Prior to Treatment Predicts Development of Psychiatric Adverse Events of HCV therapy Among HIV Co-infected individuals *J AIDS* (2012), 60:273-281.
 79. Zhang X, Daucher M, Baeza J, Kim C-W, **Kottilil S**. HIV-1 enhances HCV replication in an HCV continuous culture system expressing CD4 molecule by modulating IFN and TGF-family gene expression. *J. Med Virol* (2012), 84:1344-52.
 80. Katsounas A, Wang B, Trippler M, **Kottilil S**, Lempicki RA, Polis MA, Gerken G, Schlaak JF. CCL5 is a Marker for Early Fibrosis in Chronic Hepatitis C and is regulated by Toll-like receptor 3 signaling and Interferon- α therapy. *J. Vir Hepat* (2012), 19:128-37.
 81. Meissner E, Suffredini A. and **Kottilil S**. Proteomic Profiling of Viral infections. *Future Virology.* (2012), 7:759-65.
 82. Hubbard J, Greenwell-Wild T, Barrett L, Yang J, Lempicki RA, Wahl, SA, Asmuth DA, Murphy RL, Pollard RB, **Kottilil S**. Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with Pegylated interferon-alpha 2a. *J Infect*

- Dis* (2012), 205:1443-7.
83. Georgoff P, Thomasson D, Louie A, Fleischman E, Dutcher L, Mani H, **Kottlilil S**, Morse C, Huang C-Y, Dodd L, Kleiner DE, and Hadigan C. Clinical Utility of 1H Magnetic Resonance Spectroscopy (1H-MRS) for Measurement of Hepatic Steatosis *Am J Radiol* (2012), 99:2-7.
 84. Naggie S, Osinusi A, Katsounas A, Lempicki RA, Herrmann E, Schlaak JF, Shivakumar B, Masur H, Polis MA, **Kottlilil S**. Dysregulation Of Host Innate Immunity In HIV/HCV Genotype 1 Infected IL28B CT/TT Haplotype Patients Associated With Depressed Viral Kinetics And Therapeutic Response. *Hepatology* (2012), 56:444-54.
 85. Osinusi A, Naggie S, Herrmann E, Schlaak JF, Shivakumar , Masur H, Polis MA, **Kottlilil S**. Effect of ITPA Gene Polymorphisms on the Kinetics of Hemoglobin Declines and HCV in HIV/HCV coinfecting subjects *J. Vir Hepat* (2012), 84:1106-14.
 86. Katsounas A. Trippler M, **Kottlilil S**., Lempicki RA, Gerken G, and Schlaak JF. Cytokine/chemokine patterns connect host and viral characteristics with clinics in chronic Hepatitis C infection. *Eur J Med Res.* (2012), 11;17:9.
 87. TrehanPati N, Shrivastava S, Sukriti, Shivakumar B, Kumar B, Bose S, Tripathi DM, Das T, Sakhuja P., Rastogi A, Bhihari C, Singh S, Gupta S, **Kottlilil S**., Sarin SK. Analysis of Notch and TGF- β signaling expression in different stages of disease progression during hepatitis B infection *Clin and Transl. Gastro* (2012), 3:e23.
 88. Kohli A, Zhang X, Murphy AA, Yang J, Donnelly R, Young H, Lempicki RA, **Kottlilil S**. Differential transcriptome profiles and antiviral effect of Interféron- λ and Interféron- α on HCV infected and uninfected hepatoma cells. *J Vir. Hepat.* (2012), 19:843-53.
 89. Osinusi A, Chary A, Winters MA, **Kottlilil S**, Murphy AA, Polis MA, and Holodniy M. IL28B Polymorphism is Not Associated with HCV Protease Diversity in HIV/HCV Co-infected Patients Treated with Pegylated Interferon and Ribavirin *J. Med Virol.* (2012), 10:1522-7.
 90. Kushner LE, Wendelboe AM, Lazerroni LC, Chary A, Winters MA, Osinusi A, **Kottlilil S**, Polis, MA, Holodniy M. Immune Biomarker Differences and Changes in HCV Mono-infected and HIV/HCV Co-infected Patients. *PloS One* (2013), 8(4):e60387.
 91. Shrivasthava S, TrehanPati N, **Kottlilil S**, Sarin SK. Decline in immature transitional B cells following hepatitis B vaccination in HBV positive infants. *Ped Infect Dis.* (2013), 32(7):792-4.
 92. Shrivasthava S, TrehanPati N, Patra S, **Kottlilil S**, Pande C, Trivedi SS, Sarin SK. Increased T regulatory cells and impaired functions of circulating CD8+ T lymphocytes is associated with viral persistence in hepatitis B virus positive newborns. *J. Vir Hepat.* (2013), 20(8):582-91.
 93. Sherman AC., TrehanPati N, Brust DG, Formentini E, Daucher M, Davey RT, Masur H, Ghany M, Sarin SK, **Kottlilil S**, and Kohli A. Augmentation of HBV specific cellular immunity with PD-1/PD-L1 blockade in HBV and HIV/HBV patients treated with adefovir. *AIDS Res Hum Retr* (2013), 29(4):665-72.
 94. Katsounas A, Hubbard J, Osinusi A, Wang C, Shivakumar B, Katsounas A, Zhang X, Winter S, Polis MA, **Kottlilil S**. Induction of Interferon stimulating gene (ISG) 15 promotes HCV replication and hinders antiviral activity of Interferon-alpha. *J. Med Virol* (2013), 85(6):959-63.
 95. Zhang X., Daucher M, Armstead D, Russell R, **Kottlilil S**. Identification of Host MicroRNAs that Block HCV Replication in Vitro as Potential Targets for Treatment of

- HCV. *PLoS One* (2013), 8(2):e55733.
96. Silver, D, Osinusi, A, Newman, R, Doonquah, L, Henn, S, Teferi, G, Masur, H, **Kottilil, S.** Fishbein, D. Earlier Staging of Liver Fibrosis in African Americans with HIV-HCV Co-Infection. *Clin. Infect Dis.* (2013), 56(9):1280-3.
 97. Murphy AA, Agarwal C, Shivakumar B, Kohli A. **Kottilil S.**, Polis MA, Subramanian GM, Sood A, Midha V, Goyals O, Desai SB, Shah SR. Routine HCC Surveillance is Ineffective at Improving Mortality Without Access to HCC Treatment: Results From an Indian Cohort. *Springerplus.* (2014), 17;3:610.
 98. Kohli A, Funk EK, Shivakumar B, Sneller M, Polis MA, Masur H, Heytens L, Nelson A, Kwan R, **Kottilil S.** Treatment for HCV with Interferon and Ribavirin is Associated with Development of Hypophosphatemia in HIV/HCV Co-Infected Patients. *AIDS Res Hum Retr.* (2013), 29(9):1190-4.
 99. Osinusi A, Bon D, Nelson A, Shivakumar B, Lee YJ, Poonia S, Cai, C, Wood BJ, Haagmans BL, Lempicki R, Herrmann E, Sneller M, Polis MA, Masur H, Stanisich E, Chen C, **Kottilil S.** Comparative Efficacy, Pharmacokinetic, Pharmacodynamic Activity and ISG Expression of Different Interferon Formulations in HIV/HCV Genotype-1 Infected Patients. *J Med Virol* (2014), 86(2):177-85.
 100. Josefson L, Palmer S, Faria NR, Lemey P, Casazza D, Ambrozak D, Kearney M, Shao W, **Kottilil S,** Sneller S, Meller J, Coffin JM, and Maldarelli F. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T cells contain one HIV-1 DNA molecule. *Plos Pathogens* (2013), 9(6):e1003432.
 101. Cortez KJ, Proschan MA, Barrett L, Brust DG, Formentini E, Davey RT, Masur H, Polis MA, **Kottilil S.** Baseline CD4+ T cell counts predict HBV viral kinetics to adefovir treatment in lamivudine resistant HBV-infected patients with or without HIV infection. *HIV Clin Trials* (2013) 4(4):149-59.
 102. Osinusi A, Meissner EG, Lee Y-J, ; Bon D, Heytens L, Nelson A, Sneller M, M.D. Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan K, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Ph.D, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian GM, McHutchison JG, Polis MA, Fauci AS, Masur H, **Kottilil S.** Sofosbuvir And Ribavirin For Treatment Of Hepatitis C Genotype-1 In Patients With Unfavorable Treatment Characteristics: A Randomized Controlled Trial. *JAMA* (2013) 310:804-11.
 103. Sidharthan S, and **Kottilil S.** Mechanisms of Alcohol induced hepatocellular carcinoma. *Hepatology International.* (2014), 8(2):452-457.
 104. Katsounas A, Rasimas JJ, Papadimitriou GN, Polis MA, Gerken G, Schlaak JF, Lempicki RA, Rosenstein DL, **Kottilil S.** The role of ISG20 in Interferon- α induced neuropsychiatric toxicity along with divergent Hepatitis C Virus responses in Human Immunodeficiency Virus positive patients. *J Med Virol* (2014), 86(8):1323-31.
 105. Bon D, Meissner E, Osinusi A., Shivakumar B, Kottilil S. Porkunina L, O'Brien T, and Herrmann E. IFNL4 genotype predicts effectiveness of interferon free antiviral therapy. *J Infect Dis* (2014), 209(11):1700-4.
 106. Lee Y-J, Zhang X, Vazquez E, Siebenlist U, Young H, Shivasabeshan G, Murphy AA, Wang H, Suffredini A, **Kottilil S.** High Levels of Serum IFN α 2a as an Agonist-Antagonist of IFN α Signaling in HIV/HCV Coinfected Subjects. *J Interferon and Cytokine Research.* (2014), 34:28-34.
 107. Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, Silk R, Townsend K,

- Pang PS, Subramanian GM, McHutchison JG, Fauci AS, Masur H, **Kottilil S**. Retreatment of HCV Genotype-1 with Sofosbuvir and Ledipasvir after Relapse with Sofosbuvir and Ribavirin: A Pilot Study. *Annals Intern Med.* (2014), 61(9):634-8.
108. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, **Kottilil S**. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. *J. Clin Invest* (2014), 124(8):3352-63.
109. Funk E, **Kottilil S**, Gilliam B, and Talwani R. Selective TLR 7 agonists as antiviral agents for Hepatitis infections. *Curr Trans Med* (2014), 14;12:129.
110. Kohli A, Sherman A, **Kottilil S**. HCV treatment Paradigms: A Systematic Review. *JAMA* (2014), Aug 13;312(6):631-40.
111. **Kottilil S**. Polis MA and Masur H. Treatment of hepatitis C: When do internists take over? *Annals of Intern Med.* (2014), 161(6):443-4.
112. Kapoor R and **Kottilil S**. Advances in HBV therapeutics. *Future Virology* (2014), 9(6):565-585.
113. Swaminathan S, Sui H, Adelsberger JW, Chen Q, Sneller M, Migueles S, **Kottilil S**, Ober A, Jones S, Rehm CA, Lane HC and Imamichi T. Persistent immune activation in HIV-1 treated patients is associated with a lower level of innate immune responses via cytosolic DNA sensing systems. *J. AIDS & Clin Res.* (2014), 5:315.
114. King TH, Kemmler C, Guo Z, Mann D, Lu Y, Coeshott C, Gehring A, Bertoletti A, Ho Z, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee Y-J, **Kottilil S**, Bellgrau D, Rodell T, and Apelian D. A whole recombinant yeast-based therapeutic vaccine elicits hbv x, s and core specific t cells in mice and induces ex vivo expansion of t cells that recognize epitopes associated with viral clearance. *PLoS ONE* (2014), Jul 22;9(7):e101904. doi: 10.1371/j.
115. Meissner EG, Nelson A, Marti MM, Masur H, Osinusi A, **Kottilil S** Sustained Virologic Response for Chronic Hepatitis C Infection after 27 days of Treatment with Sofosbuvir and Ribavirin. *Open For Infec Dis* (2014), 1 (1): 013.
116. Kim C-W, Sidharthan S, Heytens L, Murphy A, Sneller MC, **Kottilil S**. Differential Gene expression profiles of PBMCs in mixed cryoglobulinemic vasculitis patients. *Frontiers in immunology* (2014), May 27;5:248.
117. Osinusi A, Odigie M, Zhang X, Imamichi T, Barrett L, Polis MA, Masur H, **Kottilil S**. IL23 promotes interferon alpha responsiveness in HIV/HCV coinfecting subjects treated with pegylated interferon and ribavirin *AIDS Hum Retr* (2014), Aug;30(8):775-82.
118. Shaffer A., Hubbard J, Barrett L, Kohli A, **Kottilil S**. A highly predictive assay to detect single nucleotide polymorphisms using serum from HIV-infected subjects. *AIDS Res Hum Retro* (2014), Aug;30(8):792.
119. Narayan S. Osinusi A., Talwani R, Funk E., **Kottilil S**. Favorable Adverse Event Profile Of Sofosbuvir/Ribavirin Compared To Boceprevir/Interferon/Ribavirin For Treatment Of Hepatitis C *Hepat International* (2014), Oct;8(4):560-6.
120. Meissner E, Osinusi A, Naggie S. Patel K, McHutchison J, Symonds W, Polis MA, Masur H, and **Kottilil S**. Effect of sofosbuvir and ribavirin on peripheral and hepatic lipid metabolism in chronic hepatitis C genotype 1 patients. *Hepatology* (2014), Mar;61(3):790-801.
121. Barrett L. Trehanpati N, Poonia S, **Kottilil S**. Hepatic compartmentalization of exhausted regulatory cells in chronic hepatitis C patients. *J Vir Hepatitis* (2015), Mar;22(3):281-8

122. Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, M.S., Marti MM, Silk R, Kotb C, Gross C, Jolley T, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, M.D. Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, **Kottlilil S.** Directly Acting Triple Drug Anti-HCV Therapy Induces Complete Virologic Response with a Six Week Regimen: A Proof of Concept Phase 2a Cohort Study. *Lancet* (2015), Mar 21;385(9973):1107-13
123. Trehanpati N, Khanam A, Hissar S, Khosla R, David P, Sehgal R, Ashish Kumar¹, Prashar A, Bhardwaj A, **Kottlilil S.**, Sarin SK. Sequential Therapy with Tenofovir plus Peg Interferon reduces T cell exhaustion and Improves Dendritic Cell phenotype and function by mir-155 regulation compared to Tenofovir monotherapy in chronic HBV patients. *J Clin & Cell Immunol.* (2015), in press.
124. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferei G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polsi MA, Fauci AS, Masur H and **Kottlilil S.** A Pilot Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in HCV Genotype 1 Subjects Coinfected with HIV Infection. *JAMA* (2015), Mar 24-31;313(12):1232-9
125. Cortez KJ and **Kottlilil S.** Beyond interferon: rationale and prospects for newer treatments in chronic hepatitis C infection. *Therapeutic Advances in Chronic Diseases.* (2015), 6(1):4-14.
126. Kohli A, Funk E, Burbelo P, Barrett L, Meissner EG, Santich B, Shaffer A, Johl J, Sidharthan S, Moir S, **Kottlilil S.** Fauci AS. Persistently Elevated Abnormal B-cell Subpopulations & Anti-core Antibodies in HIV/HCV Co-infected Patients Who Relapse. *J Med Virol* (2015), Apr;87(4):544-52.
127. Kattakuzhy S, and **Kottlilil S.** Sofosbuvir for Treatment of Chronic Hepatitis C. *Hepatology International* (2015), Apr;9(2):161-73
128. Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth D, **Kottlilil S.** Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. *Journal of AIDS Clin Research* (2015), 6(1). pii: 1000410.
129. Kohli A and **Kottlilil S.** Assessment of outcomes of Hepatitis C Treatment. *JAMA* (2014), Dec 17;312(23):2571
130. Osinusi A, Townsend K, **Kottlilil S.** Virologic response to sofosbuvir and ledipasvir in HIV/HCV coinfecting patients. *JAMA* (2015), 14;314(2):186-7
131. Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H, and **Kottlilil S.** Utility of HCV VL monitoring on Directly Acting Antoviral Therapy. *Clin Infect Dis* (2015), Jun 15;60(12):1743-51
132. Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, Roberts S, Massetto B, Ye Z, Pflanz S, Garrison KL, Gaggar A, Mani Subramanian G, McHutchison JG, **Kottlilil S.**, Freilich B, Coffin CS, Cheng W, Kim YJ. The Oral Toll Like Receptor-7 Agonist GS-9620 in patients with Chronic Hepatitis B Infection. *J Hepatology* (2015), Aug;63(2):320-8.
133. Sidharthan S, Kohli A and **Kottlilil S.** Reply to Harrington et al. *Clin Infect Dis* (2015), Aug 15;61(4):667-8

134. **Kottlil S.**, Wright M, Polis MA, Masur H, Treatment for Hepatitis C infection. *Annals of Intern Med.* (2015), Mar 17;162(6):459
135. Rower J, Meissner E, Jimmerson L, Osinusi A Sims Z, Petersen T, Bushman L, Wolfe P, McHutchison JG, **Kottlil S**, Kiser J. Serum and Cellular Ribavirin Pharmacokinetic and Concentration-Effect Analysis in HCV Patients Receiving Sofosbuvir plus Ribavirin. *J Antimicro Chemotherapy* (2015) Aug;70(8):2322-9.
136. Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, and **Kottlil S**. Hepatitis C Genotype 3 Disease. *Hepatology International* (2015), June 21, epub ahead of print.
137. Kohli A., Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang P, Osinusi A, Polis MA, Rustgi V, Masur H and **Kottlil S**. Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof of Concept Phase 2a Cohort Study. *Lancet Infect Dis* (2015), Sep;15(9):1049-54.
138. AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. *Hepatology* (2015), Sep;62(3):932-54.
139. Meissner EG, Decalf J, Casrouge A, Masur H, **Kottlil S**. Albert ML, Duffy D. Dynamic Changes of Post-translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-free Therapy. *PLOS ONE* (2015), Jul 16;10(7):e0133236.
140. Tang L and **Kottlil S**. Treatment of HCV in HIV-infected patients: no longer a challenge? *The Lancet HIV* (2015), 2(8): e308-9
141. Heill E, Hynicka LM, **Kottlil S**, Tang L. What does the pharmacological future of treating chronic hepatitis C look like. *Expert Reviews in Pharmacology* (2015), Sep;8(5):605-22.
142. Tang L, Ward H, Kattakuzhy S, Wilson E, **Kottlil S**. Dual Sofosbuvir and ribavirin therapy for hepatitis C infection. *Expert Rev in Gastro Hepatol.* (2015), 10(1):21-36.
143. Kohli, A, Kattakuzhy S., Sidharthan S., Nelson A, McLaughlin M., Seamon C, Wilson E, Meissner EG, Sims Z, Silk R.; Gross C, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M.; Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, **Kottlil S**. Four-week Directly Acting Anti-HCV Regimens in HCV Genotype-1 Patients without Cirrhosis: A Phase 2a Cohort Study. *Annals of Intern Med* (2015), 163(12):899-907.
144. Hahn K, Kohli A, Sims Z, **Kottlil S**. Durable Sustained Virologic Response after oral directly acting antiviral therapy despite immunosuppressive treatment. *Open Forum Infect Dis* (2015), 2(3):ofv091.
145. Sehgal R, Patra S, David P, Vyas A, Khanam A, Hissar S, Chibber G, **Kottlil S**, Maiwall R, Sarin SK, Trehanpati N. Impaired monocyte and macrophage functions and defective TLR signaling in hepatitis E virus infected pregnant women with acute liver failure. *Hepatology* (2015), doi: 10.1002/hep.28143.
146. Shrivastava S, Meissner EG, Funk E, Poonia S, Shokeen V, Thakur A, **Kottlil S**, Sarin SK, Trehanpati N. Elevated hepatic lipid and interferon stimulated gene expression in patients infected with hepatitis C virus genotype-3 relative to patients with non-alcoholic steatohepatitis (NASH). *Hepatology Intern* (2016), 10(6):937-94.
147. Townsend K, Petersen T, Gordon LA, Kohli A, Nelson A, Seamon C, Gross C, Tang L, Osinusi A, Polis MA, Masur H, **Kottlil S**. Effect of HIV co-infection on adherence to a 12-week regimen of regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. *AIDS* (2015), 30(2):261-6.

148. Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, Gross C, Calderon M, Proschan M, Osinusi A, Polis MA, Masur H, **Kottlilil S**, and Kohli A. High adherence to directly acting antiviral therapy in inner city HCV infected patients. *Hepatol International* (2015), 10(2):310-9.
149. Townsend K, Meissner EG, Sidharthan S, Sampson M, Remaley A, Kohli A, Osinusi A, Masur H and **Kottlilil S**. Interferon free of HCV in HIV infected subjects results in increased serum LDL levels. *Aids Hum Retr* (2015), 32(5):456-62.
150. Wilson EM, Kattakuzhy S, Sidharathan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A and **Kottlilil S**. Successful retreatment of chronic hepatitis C genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct acting antiviral regimens. *The Clin Infect Dis*, (2015) ;62(3):280-8.
151. Wilson EM and **Kottlilil S**. Eradication strategies for HBV. *Clin Infect Dis* (supplement) (2015), Jun 1;62 Suppl 4:S318-25.
152. Tang L, Ward H, Wilson E, **Kottlilil S**. Treatment of HBV: an update. *Future Microbiology*, (2016), 11:1581-1597.
153. Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, **Kottlilil S**. Favorable response to HCV treatment with directly acting antivirals correlates with changes in hepatic interferon gene expression independent of cirrhosis. (2015), *J Vir Hep* 23(7):496-505.
154. Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, **Kottlilil S**. Six-week Combination Directly Acting Anti-HCV Therapy Induces Moderate Rates of Sustained Virologic Response in Patients with Advanced Liver Disease. *Clin Infect Dis*. (2015), 62(4):440-7.
155. Petersen T, Lee YJ, Osinusi A, Amorosa V, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, **Kottlilil S** and Peters MG. Interferon Stimulated Gene Expression in HIV/HCV Co-infected Patients treated with Nitazoxanide/ Peginterferon Alfa-2a and Ribavirin *AIDS Res Hum Retr* (2016), 32(7):660-7.
156. Rosenthal E, Polis MA, **Kottlilil S**. Sofosbuvir and Ledipasvir for HIV/HCV Coinfection. *Exp Opin on Pharmacotherapy* (2016), 17(5):743-9.
157. Papudesu C and **Kottlilil S**, Bagchi S. Grazoprevir-Elbasvir for treatment of HCV Infection *Hepatol. Intern* (2016), 11(2):152-160.
158. O'Brien TR, Feld JJ, **Kottlilil S**, Pfeiffer RM. No scientific basis to restrict 8 weeks of treatment with Ledipasvir/Sofosbuvir to patients with HCV RNA <6,000,000 IU/ml. *Hepatology* (2015) 63(1):28-30
159. Poonia B and **Kottlilil S**. Newer therapeutics for hepatitis C *Annals Transl Med* 2016, 4(2):31.
160. Tang L, Marcell L, **Kottlilil S**. Systemic manifestations of hepatitis C infection. *Infections and Cancer* 2016 May 23;11:29.
161. Bean M, Tang L, **Kottlilil S**, Beavers KL, Meissner EG. On treatment elevations in hepatic transaminases during HCV treatment with ombitasvir, paritaprevir and dasabuvir. *Case Rep Infect Dis pen forum for Infect Dis* 2016. 2016:6151570 .
162. Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, **Kottlilil S**, Meissner EG, Sims Z, Hodara A, Aquilante, CL, Kiser JJ. Variant ITPA Phenotypes are Associated with

- Increased Ribavirin Triphosphate Levels. *J Clin Pharm* (2016) Jun 28. doi: 10.1002/jcph.783.
163. Emmanuel B, Shardell MD, Tracy L, **Kottlil S**, El-Kamary SS. Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III. *J Viral Hepat*. 2016 Dec 1. doi: 10.1111/jvh.12656.
 164. Emmanuel B, Sidique N, Zhang X, Poonia B, Sneller MC, **Kottlil S**, Decline in Cellular Activation in non-B cells after Rituximab Treatment in Hepatitis C-Associated Mixed Cryoglobulinemia Vasculitis *J Vir Hepatitis* 2017, 24(2):128-131.
 165. Tang L, Masur J, Nelson A, Osinusi A, Kohli A, Polis MA, and **Kottlil S** . Baseline Mental Health Disease and Hepatitis C: Impact on Sustained Virologic Response and Adherence with Interferon-Free Therapy. *W. J Hepatology* 2016. 8(31):1318-1326.
 166. Bon D, Kohli A, Osinusi A, Nelson A, **Kottlil S**, and Herrmann E. A mathematical model of HCV decay kinetics in patients receiving sofosbuvir and ledipasvir *PLoS Comp Biol*. 2017 (in press).
 167. Wilson E, Rosenthal E, Kattakuzhy S, Tang L, **Kottlil S**. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C *Clin Microbiol Rev* 2017 30(1):23-42.
 168. Bagchi S, Patel P, Faramand R, Burrowes S, Hossain MB, **Kottlil S**, Miller M, Fantry LE, Redfield RR. Underutilization of Statins for Prevention of Cardiovascular Disease Among HIV-Infected Patients. *J AIDS Clin Res* (2015) 6:9. <http://dx.doi.org/10.4172/2155-6113.1000499>.
 169. Burrowes S, Cahill P, **Kottlil S** and Bagchi S, Contribution of Antiretroviral Therapy to Cardiovascular Disease Risk in HIV-Infected Patients *Future Virology* (2016) 11(7): 509–527.
 170. Chua J, and **Kottlil S**. Sofosbuvir and Velpatasvir: A stellar option for Patients With Decompensated Cirrhosis. *Annals of Translational Medicine* 2016 S8: 48..
 171. Lee R, Wilson E, **Kottlil S**. Eradication Strategies for chronic Hepatitis B. *ID Practitioner* 2016, August 24, 2016.
 172. Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, Levy E, Sinkus R, Virtaneva K, Sturdevant D, Martens C, Porcella SF, Goodman ZD, Kanwar B, Myers RP, Subramanian M, Hadigan C, Masur H, Kleiner DE, Heller T, **Kottlil S**, Kovacs JA, Morse CG. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. *Liver Int*. 2016 May 27. doi: 10.1111/liv.13177.
 173. Mathur P, **Kottlil S**., Husson J. Management of hepatitis C infection in patients with End Stage Renal Disease. *Curr Top Infect Dis*. 2017, in press.
 174. Lee R, Wilson E, **Kottlil S**. Sofosbuvir/velpatasvir: A Pangenotypic Drug to Simplify HCV therapy *Hepatol. Intern*. 2017 (2):161-170.
 175. Jimmerson L, Clayton C, MaWhinney S, Meissner EG, Sims Z, **Kottlil S**, Kiser J. Effects of Ribavirin/Sofosbuvir/Treatment and ITPA phenotype on endogenous purines. *Antiviral Research*. 2017 138:79-85.
 176. Kattakuzhy S, Wilson E, Silk R, Akoth E, Gross C, Rosenthal E, Tang L, Masur H, **Kottlil S**. A Novel Task Shifting Model to Expand the HCV Care Continuum: the ASCEND Investigation. *Annals Intern Med*. 2017 (in press).
 177. O'Brien TR, **Kottlil S**, Feld JJ, Pfeiffer RM. Race or Genetic Makeup for HCV Treatment Decisions?. *Hepatology*. 2017 doi: 10.1002/hep.29057.

178. Trehanpati N, **Kottlilil S**, Patra S, Vasudevan M, Shgal R, David P, Vyas A, Khosla R, Khanam A, Kumar G, Hissar S, Ramakrishna G, Sarin SK. miRNA Signatures indicate Acute Liver Failure in hepatitis E infected pregnant females. *Heliyon* 2017 (in press).
179. Wyles D, Brau N, **Kottlilil S**, Daar E, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Doehle B, Huang KC, Osinusi A, McNally J, Brainard D, McHutchison JG, Naggie S, Sulkowski M. for the ASTRAL-5 investigators. Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study. *Clin Infect Dis*. 2017 (in press).
180. Shenderov M, Nelson A, Hoffmann J, Talwani R, **Kottlilil S**. A novel LIPS assay to detect HBV serologies. *Future Vir*. 2017 (in press).
181. Shrivastava S, Tang L, Osinusi A, Wilson E, Poonia B, Kohli A, **Kottlilil S**. Novel effect of NS5A inhibition on Augmentation of HCV specific immunity and SVR. *J. V Hepat*. 2017 doi: 10.1111/jvh.12702
182. Gharib AM, Thanda Han MA, , 7E, Kleiner DE, Zhao X, McLaughlin M, Matthews L, Rizvi B, Abd-Elmoniem K-Z, Sinkus R, Levy E, Koh C, Myers RP, Subramanian GM, **Kottlilil S**, Heller T, Kovacs J and Morse C. Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. 2017, *Biomed Res International* (in press)
183. Chua JV, Kottlilil S. Are we nearing the end in the fight against hepatitis C? *Expert Rev Gastroenterol Hepatol*. 2017, doi: 10.1080/17474124.2017.1309287
184. Huyen T, Nguyen T, Guedj J, Uprichard S, Kohli A, **Kottlilil S** and Perelson A. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics. *Nature Sci Reports* 2017, (in press).
185. Tang L, Covert E, Wilson E, **Kottlilil S**. Treatment of Hepatitis B infection: A Systematic Review. *JAMA* 2017, (in press)
186. Emmanuel B, Wilson EM, O'Brien T, **Kottlilil S**, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. *The Lancet Gastro & Hepatol* 2017 (in press).
187. Meissner EG, Kohli A, Higgins J, Lee Y-J, Prokunina O, Wu D, Orr C, Masur H and **Kottlilil S**. Rapid Changes in Peripheral Lymphocyte Concentrations During Interferon-free Treatment of Chronic HCV Infection. *Hepitol Comm* 2017.
188. Mercer N., Comtock E, Kottlilil S, McSweegan E, Mathur P. A novel Provider training program to escalate HCV training in high endemic regions: A Global virus Network initiative. *Antivir Research*, 2017 (in press)
189. Comstock E, Nelson A, Mathur P, Kottlilil S. Wilson E, Kattakuzhy S, Riedel D. Effectiveness of an ASCEND model training program for hepatitis C therapy in Rwanda. *Antiviral Research*, 2017 (in press)
190. Shenderov M. Tang L, **Kottlilil S**. Occult HBV Infection. *Future Virology* 2017 (in press)
191. Price A, Gross C, Akoth E, Wilson E, Osinusi A. and **Kottlilil S**. Supervised ART interruption to allow HCV therapy with DAAs in HIV/HCV coinfecting subjects *Case Rep Infect Dis* 2017, in press.
192. Younossi Z, Stepanova M, Sulkowski M, Wyles D, **Kottlilil S**, Hunt S. The Sofosbuvir and Velpatasvir Regimen is Associated with High Efficacy and Improvement of Patient-Reported Outcomes in Patients Co-infected with Hepatitis C and Human Immunodeficiency Virus: The Data from ASTRAL-5 Study. *Liver International*. 2016 (in press).

193. Abutaleb A, and **Kottilil S**. Vedroprevir: A serine protease inhibitor. *Exp Opin on Invest Drugs* 2017 (in press)
194. Emmanuel B., **Kottilil S**, Wilson E. Duration of HCV Therapy – How Short Can Therapy Be and Who Would Qualify? *AGA Perspectives*. 2017.
195. O’Brien TR, **Kottilil S**, Pfeiffer RM. *IFNL4* Genotype is Associated with Relapse for 8-Week Treatment with Sofosbuvir, Velpatasvir and Voxilaprevir. *Gastroenterology* 2017 (in press)
196. O’Brien TR, **Kottilil S**, Emmanuel B, Wilson E, Pfeiffer RM. Are we over treating Asians for hepatitis C? *Hepatology* 2017 (in press).
197. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Ledinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. *N Engl J Med*. 2017 Jun 1;376(22):2134-2146.
198. Narayan S., Abutalib A, **Kottilil S**. and Sherman KE. Mechanisms for Chronicity in HEV Infection.
199. Ridden L, **Kottilil S**. and Chua J. Treatment of hepatitis C in HIV infected patients. *Internal Medicine reviews* 2017 (in press)
200. Bagchi S, Burrowes S, Fantry LE, Hossain MB, Tollera GH, **Kottilil S**, Pauza D, Miller M, Baumgarten M, Redfield RR. Factors Associated with High Cardiovascular Risk in a Primarily African-American, Urban HIV-Infected Population *SAGE Open Med*. 2017 (in press).
201. Tang L, Parker A, Flores Y, Dellario M, Dockson C, Amoroso A, **Kottilil S**. and Wilson E. Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population. *J. Vir Hep* 2017 (in press).
202. Husson J, Ravichandran B, Jonche S, **Kottilil S**. and Wilson E. Eight weeks of ledipasvir/sofosbuvir in Kidney transplant recipients with hepatitis C genotype 1 infection *2017 Transplantation Direct* (in press)
203. Khanam A and **Kottilil S**. Defective innate immunity in acute-on chronic liver failure: immunotargets for therapeutics. 2017. *Gut* (in press).
204. Shrivastava S, Kohli A, Kottilil S. Wilson E. Multi-Target DAA Therapy is Associated with Superior Immunologic Recovery in HIV/HCV Co-Infected Patients Article Type: 2017, *J. Infect Dis*. (in press).
205. Comstock E, Kim C-W, Murphy AA, Emmanuel B, Zhang X, Sneller MC, Poonia B and **Kottilil S**. Transcriptional profiling of PBMCS unravels B cell mediated immunologic imprints in HCV vasculitis. *PLoS ONE*. 2017 (in press).
206. Mathur P, Emmanuel B, Poonia B, Sneller MC, and **Kottilil S**. B-Cell depletion therapy with rituximab in patients with hepatitis C virus mixed cryoglobulinemic vasculitis improves B- and T-Cell phenotype and function. 2017, *J Med Virol* (in press).
207. Poonia B, Nandi M, **Kottilil S**. Impaired B Cell-T follicular helper (Tfh) axis in chronic hepatitis B infection despite long term antiviral therapy. *Hep Commun* (in press).
208. Wilson E, **Kottilil S** and Poonia B. "Can directly acting antiviral regimens against hepatitis C induce host immune responses? *Future Virology* 2018 (in press).
209. Mathur P, **Kottilil S**. and Wilson E. Voseyi: A Salvage regimen for HCV 2018, *Hep Intern* (in press).

210. Abutaleb A, **Kottilil S**, Wilson E. Mayvert: A short duration therapy for HCV. 2018, *Hep Intern* (in press).
211. Rosenthal E and **Kottilil S**. Lancet G and H editorial 2018, (in press).
212. Emmanuel B, Masur H, Kottilil S. and Kattakuzhy S. Similar efficacy and safety of treatment for hepatitis C virus infection by community-based non-specialists providers in ASCEND study. 2018, *Annals Intern Med*. (in press).

Submitted or In-revision Peer-reviewed Journal Articles

1. Shah ASV, Stezle D, Lee KK, Beck EJ, Alam S, Clifford S, Longenecker C, Strachan F, Bagchi S, Whiteley W, Rajagopalan S, Kottilil S, Newby DE, Nair H, McAllister DA, Mills NL. Global burden of cardiovascular disease in people living with human immunodeficiency virus. *JAMA* 2017
2. Chaudhury C, Sheehan J, Chairez C, Akoth E, Gross C, Silk R, Kattakuzhy, Rosenthal, Kottilil S, Masur H, and Hadigan C. No Improvement in Hemoglobin A1c following Hepatitis C Viral Clearance in Patients with and without HIV Co-infection. (2017), *Clin Gastro and Hepatol* (submitted).
3. Ahmed A, Leff P, Thornton K, Kattakuzhy S, **Kottilil S**, Manch R, Kohli A. Effective Treatment of Hepatitis C by Primary Care Providers: Real World Experience. *Annals Intern Med*. 2016 (in revision).
4. Thomas A, Kattakuzhy S, Wilson E, Price A, Silk R, Akoth E, Chairez C, Kleiner DE, **Kottilil S**, and Hadigan C. Two-year Liver Histopathology Following SVR12 with Sofosbuvir and Ribavirin for Hepatitis C. *Hepatology*. 2016 (in revision).
5. Yoon J, Tang L, Sherman KE and **Kottilil S**. CCR5 and Liver fibrosis. *Infections and Cancer*. 2016 (submitted).
6. Masur J, Mody K, Shah N, **Kottilil S**, Wilson E, Shah S. Upper Normal Limit of Alanine Aminotransferase for the Indian Population. *Hepatol International*. 2016 (submitted).
7. Daigh L, Barrett L, Poonia B, **Kottilil S**. Reconstitution of Natural Killer Cells in the liver and peripheral blood with directly acting antiviral Therapy *Hepatology*. 2016 (submitted).
8. Tang L, Kamat M, Emmanuel B, Gupte P, Shukla A, **Kottilil S**, and Shah S. Comparative Antiviral Efficacy of Generic Sofosbuvir versus SOVALDI with ribavirin for the treatment of Hepatitis C *Hepatology International*. 2016 (submitted).
9. Rosenthal E, Howard L, Purdy J, Kattakuzhy S, Kohli A, Wilson E, Masur H, and **Kottilil S**. Virologic Response Following Asunaprevir/Daclatasvir with or without Beclabuvir for Treatment of HCV Genotype 1 in Patients Co-infected with HIV. *AIDS*. 2016 (in revision).
10. Wilson E, Govindan M, Tang L, **Kottilil S**. Treatment of chronic hepatitis c with ledipasvir-sofosbuvir with and without ribavirin: real-world perspectives of the impact of ribavirin. *Hepatology*. 2017 (submitted).
11. Naggie S, John-Williams L, Cyr D, Lucas J, Moseley A, **Kottilil S**, Patel K. Oxylipin bioactive metabolites as markers of inflammation and liver disease in chronic HCV infection. *Clin Gastr Hep*. 2017 (in revision).
12. Tang L, Emmanuel B, **Kottilil S**. Trends in lipid profiles with hepatitis C treatment: beyond sustained virologic response, and the influence of Interferon. *J AIDS*. 2017 (submitted).

13. **Kottlilil S**, Reddi A, Dusheiko J. Global Eradication of hepatitis C: Optimism versus realism. *The Lancet*. 2017 (submitted).
14. Esmat G, Shiha G, Abergel A, Kohli A, **Kottlilil S**, Ruane P, Naggie S, Letterio C, Hahambis TA, Natha M, Kreter B, Kersey K, Brainard D, Knox S, Doss W, Asselah T. Integrated analysis of studies evaluating the treatment of chronic hepatitis C genotype 4 with interferon free sofosbuvir based regimens. *Hepatology*. 2017 (in revision).
15. Kattakuzhy S, Masur H, **Kottlilil S**. Global Eradication of Hepatitis C: Opportunities and Challenges. *JAMA*. 2017 (submitted).
16. Rao PN, Shah SR, Chowdhury A, Sarin SK, Trehanpati N, Bhatia S, Dharamsi R, Goswami BD, Kapoor D, Luaia R, Mehta R, Mukewar S, Prasad VGM, Roop Rai R, Saigal S, Singh D, Gaggar A Knox SJ, Subramanian GM, **Kottlilil S**, Singh SP, Sood A, Varghese J, Venugopal RV. Prevalence of Host and Viral Genotypes in Patients with Chronic Hepatitis B Infection in India. *Ind J Gastro* 2017 (under review).
17. Mathur P, Emmanuel B, Sneller MC, and **Kottlilil S**. B-Cell depletion therapy with rituximab in patients with hepatitis C virus mixed cryoglobulinemic vasculitis improves B- and T-Cell phenotype and function. *J Med Virol* (submitted).

Book Chapters

1. Cortez KJ, Jackson JO, and **Kottlilil S**. Role of Chemokine and Chemokine receptors in the Pathogenesis of Infectious diseases. *In Current Topics in Membranes* (2005), 55:189.
2. Allison R, and **Kottlilil S**. Host Immune Responses in HIV Infection. *In Host Gene Responses to RNA Viral Infection* (2008), 59-82.
3. Sherman AC and **Kottlilil S**. HBV Biology: replication, Mutation and Evolution. *In HIV and Liver Disease* (2010), 125-33.
4. Tang L, **Kottlilil S**, Meissner EG *Hepatology- Virology and Pathogenesis of Hepatitis C*, in 7th edition of Zakim and Boyer's *Hepatology*. Edited by Norah Terrault (2017)
5. **Kottlilil S**, Sherman KE. Hepatitis A and E infection. *In Schiff's Diseases of the Liver*. (2017)
6. Beigel J and **Kottlilil S**. Antiviral therapy (non-HIV). *In Cecil's Textbook of Internal Medicine* (2018).
7. El-Kamary S and **Kottlilil S**. Viral Hepatitis. *In Hunter's Textbook of Tropical Medicine*. (2018).

Major Invited Speeches:

1. An invited lecture titled "Why T Cell-Mediated Immunity fails in HIV infection? A Gut Response" at Department of Pathology, University of Massachusetts, Worcester, MA on April 16, 1997.
2. An invited lecture at the Kenney Day Celebrations of Brown University School of Medicine at Memorial Hospital of Rhode Island on February 06,1998 on "Role of CTLs in HIV infection".
3. Brown University School of Medicine lecture series on HIV lecture titled "Effect of Immunotherapy in HIV Infection" on March 11, 1999.
4. Infectious Disease Grand Rounds at San Francisco General Hospital "Neurosyphilis in HIV-infected Individuals" on April 22, 1999.

5. An oral presentation titled “Innate Immune Defense Mechanisms Involved in the Control of HIV Replication: Inverse Correlation of HIV viremia with NK cell Function.” at the 9th Conference on retroviruses and Opportunistic Infections held at Seattle, during Feb 24-28, 2002.
6. An oral presentation titled “Predictive ability of HCV Viral Decay Kinetics in Predicting Treatment Response to Peginterferon Alpha 2b and Ribavirin Among HIV/HCV Co-infected Individuals” at the 2nd IAS meeting on HIV Pathogenesis held at Paris, France during July 13-16, 2003.
7. An oral presentation titled “Virologic, Biochemical and Histologic Response to Peginterferon Alpha 2b and Ribavirin Among HIV/HCV Co-infected Patients” at the 43rd ICAAC meeting held at Chicago, IL during Sept 14-17, 2003.
8. An oral presentation titled “HCV Resistance to Peginterferon/Ribavirin Therapy is associated with Increased Immune Activation in HCV/HIV Co-infected patients” at the 11th Conference on Retroviruses and Opportunistic Infections held at San Francisco, CA during Feb 07-11, 2004.
9. National Institute of Allergy & Immunology Grand Rounds on “ HIV/HCV co-infection and its Impact on HAART and Hepatotoxicity” held on April 30, 2004.
10. National Institutes of Health Clinical Research Center Grand Rounds on “HIV infection, HCV infection, and ART: The Perfect Storm” on September 15, 2004.
11. “Innate immunity in HIV infection: Enhanced NK cell-death and turnover mediated by altered expression of interferon-stimulated genes (ISG)s.” at the 12th Conference on Retrovirus and Opportunistic Infection held at Boston, MA during Feb 22-25, 2005.
12. An oral presentation titled “Differential effect of IFN on Dual (HCV and HIV) Viral Kinetics in Vivo” at the 12th International Workshop on HIV Dynamics held at Cleveland, OHIO during April 22-25, 2005.
13. An oral presentation titled “Early HCV Kinetics Prediction of SVR in HIV/HCV Co-infected Individuals Treated with Pegylated Interferon Alpha 2b and Ribavirin” at the 3rd IAS Conference on HIV Pathogenesis and Treatment, held at Rio De Janeiro, Brazil from July 24-27, 2005.
14. An oral presentation titled “Applied Proteomics in HCV/HIV Co-infection: Differential Expression of Serum Proteins Associated with Response to HCV Therapy in HIV Co-infection” at the 45th ICAAC meeting held at Washington DC from Dec 16-19, 2005.
15. Hepatology and Gastroenterology Grand Rounds titled “Genomics and Proteomics in HCV/HIV Co-infection: Differential Expression of genes and proteins associated with response to HCV Therapy in HIV Co-infection” at the Mount Sinai Hospital School of Medicine Liver conference on Feb 03, 2006.
16. NIAID Grand Rounds at the Clinical Research Center on January 19, 2007 titled “Novel insights into antiviral effects of Interferon-alpha on HCV and HIV”
17. Grand Rounds at the Jaslok Hospital, Mumbai, India titled “Applications of Genomics and Proteomics in the management of Infectious Diseases” on September 26, 2007.
18. Invited Speaker at the US-Japan Co-operative Medical Sciences Program at Portland OR on September 20, 2009.
19. Speaker at First NIH-ILBS Conference on HIV. Hepatitis and Co morbidities” held at New Delhi on March 6-7, 2010.
20. NIAID Grand Rounds Speaker on April 16, 2010 on “HBV Resistance”

21. NIH Clinical Center Grand Rounds on HIV, HCV and Liver; Struggles and Solutions” on January 19, 2011.
22. Plenary lecture on Biomarkers for HCV treatment responses at the second Latin American Symposium on Chronic Hepatitis and Liver disease held at Punta Cana, 2011.
23. Infectious Diseases Grand Rounds at Duke University on December 05, 2011.
24. Symposium Chair: 19th Conference of Retroviruses and Opportunistic infections, March 06, 2012
25. Plenary lecture: HIV and HCV coinfection at HIV Congress 2012, Mumbai, India March 16, 2012
26. Panel discussant: Turning the Tide of HIV Epidemic in the District of Columbia International AIDS Conference Washington DC July 2012.
27. Invited Speaker at HIV and Liver Disease 2012 Conference titled Immunopathogenesis of HCV and HBV in HIV infection at Jacksonhole, WY on September 07, 2012.
28. Invited Faculty speaker at the Sino-American Symposium on Translational Medicine: Liver disease Clinical research and drug induced liver injury at Shanghai, China on September 15, 2012.
29. Hepatitis C and HIV: The Borghia effect. Demystifying Medicine series held at National Institutes of Health, Bethesda campus on January 22, 2013.
30. Hepatitis C treatment update for 2013: Annual Conference of the Institute of Human Virology held at Moscow, Russia on September 12, 2013.
31. Invited Speaker at HCV Symposium: Sofosbuvir for Hepatitis C held at Institute of Liver and biliary Sciences, New Delhi, India to be held on November 15th, 2013.
32. Invited speaker at NIAAA conference on Alcohol and Liver Diseases titled “Mechanisms of Alcohol induced hepatocellular carcinoma” to be held at Hotel Ashok, New Delhi, India between November 16-18, 2013.
33. Plenary Talk on Impact of HCV infection in the USA at the National Conference on Indian Health at Billings, MT March 31, 2014.
34. Grand Rounds at Greenbaum Cancer Center, University of Maryland on “Management of HCC; an Infectious Diseases perspective” on April 4, 2014.
35. Invited talk at HIV and Liver Disease 2014 at Jacksonhole, WY September 2014 titled “Immunological strategies to eradicate HBV infection”
36. Invited Speaker at the Annual Conference of the Institute of Human Virology held at Baltimore, MD during Sept 14-17, 2014 titled “Sate of the Art of HCV management”
37. District of Columbia CFAR: city swide Seminar series: Update on Hepatitis C management May 2014.
38. Infectious Diseases Grand Rounds at University of Maryland, Baltimore on December 9, 2014 titled “Management of Hepatitis C infection: The new era of combination Directly acting antiviral agent therapy”
39. Invited Speaker at CROI Symposium 2014: HCV and Beyond: Strategies to Eradicate HBV, The Annual Conference on Retroviruses and Opportunistic Infections, 2014 held at Boston MA.
40. Invited lecture at the Annual American Association of the Study of the Liver Meeting held at Boston on November 9th 2104 titled: Once daily ledipasvir and sofosbuvir for treatment of HIV/HCV coinfectd genotype 1 subjects: Final results of the ERADICATE study.

41. Invited Hematology/Oncology Grand Rounds: Greenebaum Cancer Center lecture at the University of Maryland, on December 18th, 2014 on “Antiviral Strategies to prevent hepatocellular carcinoma”
42. Medical Grand Rounds at KEM Hospital on Management of HCV infection in 2015 on February 6, 2015
43. Gastroenterology Grand Rounds on Control and Eradication of Chronic Hepatitis C Infection on February 6, 2015 at Global Hospitals, Mumbai, India.
44. Medicine Grand Rounds at the Institute of Liver and Biliary Sciences on HCV in 2015 on February 10, 2015
45. Basic Science Grand Rounds at the Institute of Liver and Biliary Sciences on “Current Approaches to Eradicate Chronic HBV Infection on February 9, 2015
46. Greenebaum Cancer Center Population Sciences Lecture on “Implications of City Wide Eradication of HCV; The ASCEND Study” on February 18th, 2015
47. “Adaptive strategies to cure chronic hepatitis B” Invited lecture at NIAID ACTG Hepatitis Transformative Sciences Group (TSG) held on February 27, 2015
48. Invited lecture at the IAS-USA Improving the management of HIV Disease Course on “HIV/HCV Coinfection: New Drugs and Drug Drug Interactions” on May 13, 2015.
49. Invited lecture on “Strategies to eradicate HBV infection” at Digestive Diseases Week, to be held at Washington DC, May 2015
50. Invited lecture at the Asia Pacific Study of Liver Single topic Conference at New Delhi on December 16, 2015 titled “ Management of Hepatitis C infection”
51. Invited Lecture at ID week Novel Drugs in Development to Control or Eradicate Hepatitis B infection on October 8th, 2015.
52. Invited lecture at the 16th International Workshop on The Pharmacology of HIV and Hepatitis on “HBV Therapy: What is in the Pipeline? On May 26, 2015.
53. Medicine Grand Rounds at University of Maryland School of Medicine on October 07, 2015 Hepatitis C update
54. Invited lecture at the Seventh Annual Global Virus Network Meeting at Beijing, China on May 17, 2015 on hepatitis C treatment advances in 2015.
55. Invited lecture on “hepatitis virus” at Short course of Global Virus Network, held at Baltimore on July 10, 2015
56. Invited lecture at HEDART meeting held between December 06-10, 2015 at Maui, HI on “Ultra short courses for HCV therapy”
57. Expert Panel Participant on the future of HCV therapy at national Summit held at Washington DC on June 4th, 2015
58. Plenary lecture on “Evolution of resistance in HCV infection” at APASL Single Topic Conference on December 17, 2015
59. Post graduate Course lecture on “Management of lecture on evolution of resistance in HCV infection at APASL Single Topic Conference on December 18, 2015
60. Plenary lecture on “Management of HCV genotype 3 infection” at APASL Single Topic Conference on December 18, 2015
61. University of Maryland School of Medicine Grand Rounds on HCV management: accomplishments and Challenges” on March 12, 2016
62. Invited lecture at the 2016 Spring Symposium of Greater Washington Infectious Diseases Society on “Strategies to Eradicate HBV infection” held on March 9, 2016

63. Invited lecture at the 17th International Workshop on The Pharmacology of HIV and Hepatitis on “HBV Therapy: What is in the Pipeline? On May 26, 2015.
64. National Institutes of Health Clinical Research Center Grand Rounds on Current Trends of HCV management: Strategy to Global Elimination of HCV” on June 22, 2016.
65. Invited Medicine Grand Rounds on “Management of Hepatitis C for the Internist” on August 19, 2016 at the Harbor East Medstar Hospital, Baltimore, MD
66. Invited lecture on Prevention of hepatocellular Carcinoma using Functional cure of HBV infection” to Tumor Immunology Group, University of Maryland, Baltimore, MD
67. An Invited Plenary lecture on “ HCV Therapy: Accomplishments and Challenges” on the World Hepatitis Day Celebration at Rwanda Ministry of Health Workshop in Kigali, Rwanda on July 28, 2016.
68. An Invited lecture titled “HCV management_2016” at the Annual Meeting of the Global Virus Network in Sapporo, Japan on October 25th, 2016.
69. An invited lecture on “the role of immune check point inhibitor therapy for HIV, HCV and HBV infections’ at Jacksonhole, WY on September 17, 2016
70. An invited lecture on “Functional cure for HBV infection” at the Annual Meeting of the Institute of Human virology at Baltimore on September 22nd, 2016.
71. An invited Plenary lecture on HCV management challenges at the 2nd Annual Conference on Liver diseases at Kolkata, India on December 1st, 2016.
72. Research talk on final results of the ASTRAL-5 study at the 17th Annual Meeting of the Asia Pacific Association on the Study of the Liver: held at Shanghai on February 18th, 2017
73. Medical Grand Rounds at Emory University on March 16th titled “ rationale for ultra short course therapy for HCV” at Atlanta
74. An invited special lecture on “HCV-driven Cancers” during the conference on infectious agents and cancers at Naples, Italy on March 23rd, 2017
75. An invited symposium on “ Hepatitis E: When Why and Where?” at Digestive Diseases week to be held at Chicago on May 6th, 2017
76. An invited talk on “Research Matters in Cancer Symposium” held at Johns Hopkins University on April 12, 2017.
77. An invited talk on “Current Management of hepatitis C” held at King’s college, London on May 23rd, 2017
78. Chair, Session on “Cardiovascular and Liver Complications associated with HIV infection” October 26, 2017 at the Annual IHV Meeting held in Baltimore, MD
79. An invited talk on “Hepatitis C management in 2017” at the Global Virus Network Annual Meeting in Melbourne, Australia on September 24, 2017.
80. An invited talk on “Hepatitis Viruses” held at the Global virus Network Short course, held on August 14th, 2017.
81. An invited talk at the HEPDART 2017 meeting held at Kona, HI on “Short duration Therapy for hepatitis C” on December 3, 2017.
82. An invited talk on “Immune based strategies to achieve a functional cure for hepatitis B infection” held at University of Maryland Greenebaum Cancer Center Tumor immunology immunotherapy Retreat held on August 4th, 2017.
83. An invited talk on “Opportunities and Challenges to escalate hepatitis C treatment” update” on World Hepatitis Day Meeting in Kigali, Rwanda on July 28th, 2017.

84. Plenary talk at the 64th Annual AUA meeting titled “Beginning of the end of hepatitis C in 2017” held at Washington DC on May 04, 2017
85. Medical Grand rounds on management of hepatitis C at the MedStar Harbor east Hospital on September 1, 2017